0001193125-23-046036.txt : 20230223 0001193125-23-046036.hdr.sgml : 20230223 20230223120509 ACCESSION NUMBER: 0001193125-23-046036 CONFORMED SUBMISSION TYPE: N-CSR PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 EFFECTIVENESS DATE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: T. Rowe Price Equity Funds, Inc. CENTRAL INDEX KEY: 0001012968 IRS NUMBER: 000000000 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-CSR SEC ACT: 1940 Act SEC FILE NUMBER: 811-07639 FILM NUMBER: 23657988 BUSINESS ADDRESS: STREET 1: 100 EAST PRATT STREET CITY: BALTIMORE STATE: MD ZIP: 21202 BUSINESS PHONE: 410-345-2000 MAIL ADDRESS: STREET 1: 100 EAST PRATT STREET CITY: BALTIMORE STATE: MD ZIP: 21202 FORMER COMPANY: FORMER CONFORMED NAME: T. Rowe Price Institutional Equity Funds, Inc. DATE OF NAME CHANGE: 20051028 FORMER COMPANY: FORMER CONFORMED NAME: T ROWE PRICE INSTITUTIONAL EQUITY FUNDS INC DATE OF NAME CHANGE: 20011105 FORMER COMPANY: FORMER CONFORMED NAME: INSTITUTIONAL DOMESTIC EQUITY FUNDS INC DATE OF NAME CHANGE: 19960428 0001012968 S000002094 T. Rowe Price Institutional Small-Cap Stock Fund C000005462 T. Rowe Price Institutional Small-Cap Stock Fund TRSSX N-CSR 1 d269721dncsr.htm INSTITUTIONAL SMALL-CAP STOCK FUND_SCI_E129-050 Institutional Small-Cap Stock Fund_SCI_E129-050

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED

MANAGEMENT INVESTMENT COMPANIES

Investment Company Act File Number: 811-07639

T. Rowe Price Equity Funds, Inc.

 

(Exact name of registrant as specified in charter)

100 East Pratt Street, Baltimore, MD 21202                

 

(Address of principal executive offices)

David Oestreicher

100 East Pratt Street, Baltimore, MD 21202

 

(Name and address of agent for service)

Registrant’s telephone number, including area code: (410) 345-2000

Date of fiscal year end: December 31

Date of reporting period: December 31, 2022

 


Item 1. Reports to Shareholders

(a) Report pursuant to Rule 30e-1


Annual
REPORT
December
31,
2022
Institutional
Small-Cap
Stock
Fund
T.
ROWE
PRICE
For
more
insights
from
T.
Rowe
Price
investment
professionals,
go
to
troweprice.com
.
Highlights
and
Market
Commentary
Management’s
Discussion
of
Fund
Performance
Performance
and
Expenses
Financial
Highlights
Portfolio
of
Investments
Financial
Statements
and
Notes
Additional
Fund
Information
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
HIGHLIGHTS
The
Institutional
Small-Cap
Stock
Fund
declined
and
underperformed
the
Russell
2000
Index
in
a
year
marked
by
Russia’s
invasion
of
Ukraine,
elevated
inflation
exacerbated
by
rising
commodity
prices
and
global
supply
chain
disruptions,
tightening
financial
conditions,
and
slowing
economic
and
corporate
earnings
growth.
The
consumer
discretionary
and
energy
sectors
were
the
largest
detractors
from
the
fund’s
performance
relative
to
the
benchmark,
while
holdings
in
information
technology
added
value.
Bottom-up
stock
selection
continued
to
drive
our
portfolio
positioning.
We
sought
companies
that
are
solving
hard
problems,
believing
that
they
will
be
successful
regardless
of
the
macro
environment.
The
economic
backdrop
remains
challenged,
and
we
are
not
ruling
out
additional
downside
from
here,
but
we
maintain
conviction
in
our
investment
process
regardless
of
these
factors
and
believe
our
focus
on
identifying
the
advantaged
companies
across
our
universe
that
offer
relative
value
will
provide
strong
long-term
results.
Log
in
to
your
account
at
troweprice.com
for
more
information.
*
Certain
mutual
fund
accounts
that
are
assessed
an
annual
account
service
fee
can
also
save
money
by
switching
to
e-delivery.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
Market
Commentary
1
Dear
Investor
Nearly
all
major
global
stock
and
bond
indexes
fell
sharply
in
2022,
as
investors
contended
with
persistently
high
inflation,
tightening
financial
conditions,
and
slowing
economic
and
corporate
earnings
growth.
Double-digit
losses
were
common
in
equity
markets
around
the
world,
and
bond
investors
also
faced
a
historically
tough
environment
amid
a
sharp
rise
in
interest
rates.
Value
shares
declined
but
outperformed
growth
stocks
by
a
considerable
margin
as
equity
investors
turned
risk
averse
and
as
rising
rates
put
downward
pressure
on
growth
stock
valuations.
Emerging
markets
stocks
generally
underperformed
shares
in
developed
markets.
Meanwhile,
the
U.S.
dollar
strengthened
versus
most
currencies
during
the
period,
which
weighed
on
returns
for
U.S.
investors
in
international
securities.
Within
the
S&P
500
Index,
energy
was
a
rare
bright
spot,
gaining
more
than
60%
as
oil
prices
jumped
in
response
to
Russia’s
invasion
of
Ukraine
and
concerns
over
commodity
supply
shortages.
Defensive
shares,
such
as
utilities,
consumer
staples,
and
health
care,
held
up
relatively
well
and
finished
the
year
with
roughly
flat
returns.
Conversely,
communication
services,
consumer
discretionary,
and
information
technology
shares
suffered
the
largest
declines.
Elevated
inflation
remained
a
leading
concern
for
investors
throughout
the
period,
although
there
were
signs
that
price
increases
were
moderating
by
year-end.
November’s
consumer
price
index
data
showed
headline
inflation
rising
7.1%
on
a
12-month
basis,
the
lowest
level
since
December
2021
but
still
well
above
the
Federal
Reserve’s
2%
long-term
target.
In
response
to
the
high
inflation
readings,
global
central
banks
tightened
monetary
policy,
and
investors
focused
on
communications
from
central
bank
officials
on
how
high
rates
would
have
to
go.
The
Fed,
which
at
the
end
of
2021
had
forecast
that
it
would
only
need
to
raise
interest
rates
0.75
percentage
point
in
all
of
2022,
raised
its
short-term
lending
benchmark
from
near
zero
in
March
to
a
target
range
of
4.25%
to
4.50%
by
December
and
indicated
that
additional
hikes
are
likely.
Bond
yields
increased
considerably
across
the
U.S.
Treasury
yield
curve
as
the
Fed
tightened
monetary
policy,
with
the
yield
on
the
benchmark
10-year
U.S.
Treasury
note
climbing
from
1.52%
at
the
start
of
the
period
to
3.88%
at
the
end
of
the
year.
Significant
inversions
in
the
yield
curve,
which
are
often
considered
a
warning
sign
of
a
coming
recession,
occurred
during
the
period
as
shorter-maturity
Treasuries
experienced
the
largest
yield
increases.
The
sharp
increase
in
yields
led
to
historically
weak
results
across
the
fixed
income
market,
with
the
Bloomberg
U.S.
Aggregate
Bond
Index
delivering
its
worst
year
on
record.
(Bond
prices
and
yields
move
in
opposite
directions.)
As
the
period
came
to
an
end,
the
economic
backdrop
appeared
mixed.
Although
manufacturing
gauges
have
drifted
toward
contraction
levels,
the
U.S.
jobs
market
remained
resilient,
and
corporate
and
household
balance
sheets
appeared
strong.
Meanwhile,
the
housing
market
has
weakened
amid
rising
mortgage
rates.
The
past
year
has
been
a
trying
time
for
investors
as
few
sectors
remained
untouched
by
the
broad
headwinds
that
markets
faced,
and
volatility
may
continue
in
the
near
term
as
central
banks
tighten
policy
amid
slowing
economic
growth.
However,
in
our
view,
there
continue
to
be
opportunities
for
selective
investors
focused
on
fundamentals.
Valuations
in
most
global
equity
markets
have
improved
markedly,
although
U.S.
equities
still
appear
relatively
expensive
by
historical
standards,
while
bond
yields
have
reached
some
of
the
most
attractive
levels
since
the
2008
global
financial
crisis.
We
believe
this
environment
makes
skilled
active
management
a
critical
tool
for
identifying
risks
and
opportunities,
and
our
investment
teams
will
continue
to
use
fundamental
research
to
identify
securities
that
can
add
value
to
your
portfolio
over
the
long
term.
Thank
you
for
your
continued
confidence
in
T.
Rowe
Price.
Sincerely, 
Robert
Sharps
CEO
and
President
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
Management’s
Discussion
of
Fund
Performance
2
INVESTMENT
OBJECTIVE 
The
fund
seeks
to
provide
long-term
capital
growth
by
investing
primarily
in
stocks
of
small
companies.
FUND
COMMENTARY
How
did
the
fund
perform
in
the
past 12
months?
The
Institutional
Small-Cap
Stock
Fund
returned
-23.31%
for
2022.
The
fund
underperformed
the
Russell
2000
Index
but
outperformed
the
Lipper
Small-Cap
Growth
Funds
Index.
(
Past
performance
cannot
guarantee
future
results
.)
What
factors
influenced
the
fund’s
performance?
The
challenges
discussed
in
our
semiannual
letter
persisted
in
the
latter
half
of
the
year;
indeed,
2022
was
the
worst
year
for
equities
since
the
2008
global
financial
crisis
and
the
third-
worst
calendar
year
for
the
Russell
2000
Index
since
its
inception.
The
year
was
marked
by
Russia’s
invasion
of
Ukraine,
elevated
inflation
exacerbated
by
rising
commodity
prices
and
global
supply
chain
disruptions,
tightening
financial
conditions,
and
slowing
economic
and
corporate
earnings
growth.
Growth
stocks
were
especially
pressured
in
a
rising
interest
rate
environment,
and
our
tilt
toward
growth
hindered
relative
performance.
Stock
selection
in
consumer
discretionary,
an
area
especially
hampered
by
inflation
and
expectations
of
a
recession,
weighed
most
heavily
on
relative
results.
An
underweight
allocation
to
energy
also
detracted.
On
the
positive
side,
our
holdings
in
information
technology
added
value.
In
consumer
discretionary,
our
holding
in
electric
vehicle
manufacturer
Rivian
Automotive
detracted
most
significantly.
Following
a
highly
anticipated
initial
public
offering
at
the
end
of
2021,
shares
of
Rivian
fell
sharply
in
2022.
In
addition
to
market
sentiment
headwinds
weighing
broadly
on
growth
stocks,
the
company
faced
significant
supply
chain
disruption
and
increased
competition.
While
some
growing
pains
and
near-term
headwinds
may
persist,
our
long-term
outlook
remains
intact.
We
like
the
company’s
experienced
management
team,
its
focus
on
profitable
market
segments,
and
its
positioning
as
a
beneficiary
of
the
secular
trend
of
electrification.
A
challenging
consumer
backdrop
also
weighed
on
shares
of
omnichannel
vision
care
provider
Warby
Parker.
We
believe
Warby
Parker
is
a
best‐in‐class
company
with
leading
technology,
exceptional
customer
service,
and
vast
opportunity
for
growth
as
brand
awareness
increases.
(Please
refer
to
the
portfolio
of
investments
for
a
complete
list
of
holdings
and
the
amount
each
represents
in
the
portfolio.)
Less
exposure
to
energy
also
hindered
relative
results.
Energy
stocks
produced
extraordinary
gains,
surging
with
oil
and
natural
gas
prices
during
the
year,
as
many
nations
sanctioned
Russia
and
made
efforts
to
reduce
reliance
on
Russian
energy
exports
because
of
its
invasion
of
Ukraine.
On
the
positive
side,
stock
selection
in
information
technology
contributed
the
most
to
relative
results.
Shares
of
our
longtime
holding
in
Lattice
Semiconductor
fell,
but
the
stock
outperformed
the
technology
sector,
which
was
the
second-
worst-performing
sector
in
the
benchmark.
The
company
continued
to
make
progress
in
its
turnaround
efforts,
initiated
by
new
management,
and
stands
to
benefit
from
several
growth
drivers,
including
5G
technology
and
automotive
electrification,
in
our
view.
Shares
of
Teledyne
Technologies
declined
modestly
but
also
outpaced
the
broader
sector.
Teledyne
is
an
industrial
technologies
conglomerate,
with
a
core
focus
on
industrial
sensors.
Increasing
demand
for
precision
sensors
and
imaging
should
create
tailwinds
for
the
company,
and
we
believe
it
has
an
opportunity
to
improve
margins
and
cash
flows
and
generate
growth
through
thoughtful
capital
deployment.
How
is
the
fund
positioned?
Bottom-up
stock
selection
continued
to
drive
our
portfolio
positioning.
We
sought
companies
that
are
solving
hard
problems,
believing
that
they
will
be
successful
regardless
of
the
macro
environment.
Purchases
spanned
the
various
sectors,
with
some
of
the
larger
buys
occurring
within
our
biggest
sector
weightings:
health
care
and
financials.
On
the
other
hand,
we
sold
holdings
that
were
acquired
or
performed
well
or
where
our
conviction
has
begun
to
wane,
and
we
used
proceeds
to
fund
names
that
have
come
under
pressure
recently.
Within
health
care,
our
focus
is
on
identifying
investments
that
we
believe
will
thrive
regardless
of
potential
regulatory
headwinds.
Our
largest
allocation
is
to
the
biotechnology
industry,
and
we
found
some
new
ideas
here,
including
commercial
biologics
contract
development
and
manufacturing
company
Avid
Bioservices.
We
believe
the
company
is
capable
of
significant
revenue
growth
and
margin
expansion
in
the
next
three
to
five
years.
We
also
initiated
on
Ionis
Pharmaceuticals,
a
commercial-stage
biotechnology
company
built
around
its
antisense
drug
discovery
platform.
Antisense
drugs
can
modulate
the
production
of
disease-
causing
proteins
at
the
gene
level.
We
believe
the
company’s
pipeline,
with
multiple
high-probability
trials
pending,
offers
PERFORMANCE
COMPARISON
Total
Return
Periods
Ended
12/31/22
6
Months
12
Months
Institutional
Small-Cap
Stock
Fund
1.95‌%
-23.31‌%
Russell
2000
Index
3.91‌
-20.44‌
Lipper
Small-Cap
Core
Funds
Index
4.94‌
-15.22‌
Lipper
Small-Cap
Growth
Funds
Index
2.63‌
-26.54‌
S&P
500
Index
2.31‌
-18.11‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
3
significant
growth
potential.
Our
next
largest
exposures
are
to
the
more
value-oriented
health
care
providers
and
services
and
health
care
equipment
and
supplies
industries.
We
added
a
position
in
medical
technology
company
Masimo.
It
specializes
in
noninvasive
patient
monitoring
technologies,
medical
devices,
and
sensors.
Within
financials,
our
largest
industry
exposure
is
to
banks.
We
feel
there
are
opportunities
within
regional
banks
with
strong
management
teams,
improving
credit
metrics,
reasonable
valuations,
and
solid
balance
sheets.
The
period
was
especially
challenging
for
growth-focused
banks,
as
investors
worried
that
growth
in
deposits
could
come
at
the
expense
of
asset
quality.
We
took
advantage
of
these
pricing
dislocations
to
add
select
companies
to
the
fund.
We
found
an
attractive
entry
point
in
Cadence
Bank.
The
company
was
formed
via
a
merger
of
equals
between
Bancorp
South
and
legacy
Cadence
in
late
2021.
We
believe
that
the
combination
created
a
premier
bank
with
scale
across
some
of
the
best
growth
markets
in
the
country.
We
also
added
a
position
in
Veritex
Holdings,
a
high-growth,
high-performing
commercial
bank
based
in
Texas.
We
like
the
company’s
position
in
attractive
metro
markets
and
its
commercial
focus.
High-level
sales
rationales
included
acquisitions,
strong
share
price
appreciation,
and
changes
to
our
investment
thesis.
Acquisition-driven
top
sales
included
the
elimination
of
real
estate
holdings
American
Campus
and
PS
Business
Parks
and
industrials
and
business
services
name
Meritor.
We
exited
Matson,
a
marine
shipping
company,
on
strength
following
solid
execution
in
response
to
the
unprecedented
demand
resulting
from
global
logistics
bottlenecks.
Stocks
that
were
trimmed
following
runups
in
price
included
Medicaid
managed
care
company
Molina
Healthcare
and
management
consulting,
technology,
and
engineering
services
company
Booz
Allen
Hamilton
Holding.
We
eliminated
communication
services
provider
Cable
One
as
competitive
pressures,
rising
interest
rates,
and
the
possibility
of
increased
regulation
weakened
our
conviction
in
its
long-term
potential.
What
is
portfolio
management’s
outlook?
The
economic
backdrop
remains
challenged,
and
we
believe
that
the
impact
of
the
Fed’s
rate
hiking
should
begin
to
show
through
company
earnings
in
the
next
few
quarters.
We
are
not
ruling
out
additional
downside
from
here,
but
the
market
is
looking
for
any
reason
to
rally,
and
we
would
not
be
surprised
if
it
did
should
there
be
news
that
the
Fed
may
be
taking
its
foot
off
the
brakes.
While
we
monitor
these
macroeconomic
factors,
we
do
not
make
top-down
adjustments
to
the
portfolio
in
response.
Although
we
cannot
say
that
we’ve
reached
the
bottom
of
this
sell-off,
we
maintain
conviction
in
our
investment
process,
remain
focused
on
identifying
the
advantaged
companies
across
our
universe
that
offer
relative
value,
and
believe
that
our
fundamental
and
patient
approach
will
provide
strong
long-term
results.
The
views
expressed
reflect
the
opinions
of
T.
Rowe
Price
as
of
the
date
of
this
report
and
are
subject
to
change
based
on
changes
in
market,
economic,
or
other
conditions.
These
views
are
not
intended
to
be
a
forecast
of
future
events
and
are
no
guarantee
of
future
results.
SECTOR
DIVERSIFICATION
Percent
of
Net
Assets
6/30/22
12/31/22
Health
Care
17.9‌%
18.4‌%
Financials
16.9‌ 
16.8‌ 
Industrials
and
Business
Services
15.3‌ 
15.8‌ 
Information
Technology
13.7‌ 
13.5‌ 
Consumer
Discretionary
11.3‌ 
10.8‌ 
Real
Estate
5.1‌ 
5.1‌ 
Energy
4.2‌ 
4.7‌ 
Consumer
Staples
4.1‌ 
4.2‌ 
Utilities
4.3‌ 
3.8‌ 
Materials
3.4‌ 
3.4‌ 
Communication
Services
1.8‌ 
0.5‌ 
Other
and
Reserves
2.0‌ 
3.0‌ 
Total
100.0‌%
100.0‌%
Historical
weightings
reflect
current
industry/sector
classifications.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
4
RISKS
OF
INVESTING
IN
THE
INSTITUTIONAL
SMALL-
CAP
STOCK
FUND
Stocks
generally
fluctuate
in
value
more
than
bonds
and
may
decline
significantly
over
short
time
periods.
There
is
a
chance
that
stock
prices
overall
will
decline
because
stock
markets
tend
to
move
in
cycles,
with
periods
of
rising
and
falling
prices.
The
value
of
a
stock
in
which
the
fund
invests
may
decline
due
to
general
weakness
in
the
U.S.
stock
market,
such
as
when
the
U.S.
financial
markets
decline,
or
because
of
factors
that
affect
a
particular
company
or
industry.
Because
the
fund
may
hold
stocks
with
either
growth
or
value
characteristics,
it
could
underperform
other
stock
funds
that
take
a
strictly
growth
or
value
approach
to
investing
when
one
style
is
currently
in
favor.
Growth
stocks
tend
to
be
more
volatile
than
the
overall
stock
market
and
can
have
sharp
price
declines
as
a
result
of
earnings
disappointments.
Value
stocks
carry
the
risk
that
the
market
will
not
recognize
their
intrinsic
value
or
that
they
are
actually
appropriately
priced
at
a
low
level.
Because
the
fund
invests
primarily
in
securities
issued
by
small-cap
companies,
it
is
likely
to
be
more
volatile
than
a
fund
that
focuses
on
securities
issued
by
larger
companies.
Small
companies
often
have
less
experienced
management,
narrower
product
lines,
more
limited
financial
resources,
and
less
publicly
available
information
than
larger
companies.
In
addition,
smaller
companies
are
typically
more
sensitive
to
changes
in
overall
economic
conditions,
and
their
securities
may
be
difficult
to
trade.
BENCHMARK
INFORMATION
Note:
Portions
of
the
mutual
fund
information
contained
in
this
report
was
supplied
by
Lipper,
a
Refinitiv
Company,
subject
to
the
following:
Copyright
2023
©
Refinitiv.
All
rights
reserved.
Any
copying,
republication
or
redistribution
of
Lipper
content
is
expressly
prohibited
without
the
prior
written
consent
of
Lipper.
Lipper
shall
not
be
liable
for
any
errors
or
delays
in
the
content,
or
for
any
actions
taken
in
reliance
thereon.
Note:
London
Stock
Exchange
Group
plc
and
its
group
undertakings
(collectively,
the
“LSE
Group”).
©
LSE
Group
2023.
FTSE
Russell
is
a
trading
name
of
certain
of
the
LSE
Group
companies.  “Russell
®
” is/are
a
trademark(s)
of
the
relevant
LSE
Group
companies
and
is/are
used
by
any
other
LSE
Group
company
under
license.
All
rights
in
the
FTSE
Russell
indexes
or
data
vest
in
the
relevant
LSE
Group
company
which
owns
the
index
or
the
data.
Neither
LSE
Group
nor
its
licensors
accept
any
liability
for
any
errors
or
omissions
in
the
indexes
or
data
and
no
party
may
rely
on
any
indexes
or
data
contained
in
this
communication.
No
further
distribution
of
data
from
the
LSE
Group
is
permitted
without
the
relevant
LSE
Group
company’s
express
written
consent.
The
LSE
Group
does
not
promote,
sponsor
or
endorse
the
content
of
this
communication.
The
LSE
Group
is
not
responsible
for
the
formatting
or
configuration
of
this
material
or
for
any
inaccuracy
in
T.
Rowe
Price’s
presentation
thereof.
Note:
Copyright
©
2023,
S&P
Global
Market
Intelligence
(and
its
affiliates,
as
applicable).
Reproduction
of
any
information,
data
or
material,
including
ratings
("Content")
in
any
form
is
prohibited
except
with
the
prior
written
permission
of
the
relevant
party. Such
party,
its
affiliates
and
suppliers
("Content
Providers")
do
not
guarantee
the
accuracy,
adequacy,
completeness,
timeliness
or
availability
of
any
Content
and
are
not
responsible
for
any
errors
or
omissions
(negligent
or
otherwise),
regardless
of
the
cause,
or
for
the
results
obtained
from
the
use
of
such
Content.
In
no
event
shall
Content
Providers
be
liable
for
any
damages,
costs,
expenses,
legal
fees,
or
losses
(including
lost
income
or
lost
profit
and
opportunity
costs)
in
connection
with
any
use
of
the
Content.
A
reference
to
a
particular
investment
or
security,
a
rating
or
any
observation
concerning
an
investment
that
is
part
of
the
Content
is
not
a
recommendation
to
buy,
sell
or
hold
such
investment
or
security,
does
not
address
the
appropriateness
of
an
investment
or
security
and
should
not
be
relied
on
as
investment
advice.
Credit
ratings
are
statements
of
opinions
and
are
not
statements
of
fact.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
5
TWENTY-FIVE
LARGEST
HOLDINGS
Percent
of
Net
Assets
12/31/22
Lattice
Semiconductor
1.4‌%
Ingersoll
Rand
1.2‌ 
Molina
Healthcare
1.2‌ 
Burlington
Stores
1.2‌ 
Selective
Insurance
Group
1.1‌ 
Teledyne
Technologies
1.1‌ 
FirstService
1.1‌ 
Element
Solutions
1.0‌ 
EastGroup
Properties
1.0‌ 
Argenx
1.0‌ 
Papa
John's
International
1.0‌ 
Magnolia
Oil
&
Gas
1.0‌ 
Bruker
0.9‌ 
PennyMac
Financial
Services
0.8‌ 
Boston
Beer
0.8‌ 
Ollie's
Bargain
Outlet
Holdings
0.8‌ 
Diamondback
Energy
0.8‌ 
Venture
Global
LNG
0.8‌ 
Axis
Capital
Holdings
0.8‌ 
Assurant
0.7‌ 
Descartes
Systems
Group
0.7‌ 
Western
Alliance
Bancorp
0.7‌ 
Ascendis
Pharma
0.7‌ 
Entegris
0.7‌ 
Clear
Secure
0.7‌ 
Total
23.2‌%
Note:
The
information
shown
does
not
reflect
any
exchange-traded
funds
(ETFs),
cash
reserves,
or
collateral
for
securities
lending
that
may
be
held
in
the
portfolio.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
6
GROWTH
OF
$1
MILLION 
This
chart
shows
the
value
of
a
hypothetical
$1
million
investment
in
the
fund
over
the
past
10
fiscal
year
periods
or
since
inception
(for funds
lacking
10-year
records).
The
result
is
compared
with
benchmarks,
which
include
a
broad-based
market
index
and
may
also
include
a
peer
group
average
or
index.
Market
indexes
do
not
include
expenses,
which
are
deducted
from
fund returns
as
well
as
mutual fund
averages
and
indexes.
INSTITUTIONAL
SMALL-CAP
STOCK
FUND
AVERAGE
ANNUAL
COMPOUND
TOTAL
RETURN
EXPENSE
RATIO
FUND
EXPENSE
EXAMPLE
As
a
mutual
fund
shareholder,
you
may
incur
two
types
of
costs:
(1)
transaction
costs,
such
as
redemption
fees
or
sales
loads,
and
(2)
ongoing
costs,
including
management
fees,
distribution
and
service
(12b-1)
fees,
and
other
fund
expenses.
The
following
example
is
intended
to
help
you
understand
your
ongoing
costs
(in
dollars)
of
investing
in
the
fund
and
to
compare
these
costs
with
the
ongoing
costs
of
investing
in
other
mutual
funds.
The
example
is
based
on
an
investment
of
$1,000
invested
at
the
beginning
of
the
most
recent
six-month
period
and
held
for
the
entire
period.
Actual
Expenses
The
first
line
of
the
following
table
(Actual)
provides
information
about
actual
account
values
and
actual
expenses.
You
may
use
the
information
on
this
line,
together
with
your
account
balance,
to
estimate
the
expenses
that
you
paid
over
the
period.
Simply
divide
your
account
value
by
$1,000
(for
example,
an
$8,600
account
value
divided
by
$1,000
=
8.6),
then
multiply
the
result
by
the
number
on
the
first
line
under
the
heading
“Expenses
Paid
During
Period”
to
estimate
the
expenses
you
paid
on
your
account
during
this
period.
Hypothetical
Example
for
Comparison
Purposes
The
information
on
the
second
line
of
the
table
(Hypothetical)
is
based
on
hypothetical
account
values
and
expenses
derived
from
the
fund’s
actual
expense
ratio
and
an
assumed
5%
per
year
rate
of
return
before
expenses
(not
the
fund’s
actual
return).
You
may
compare
the
ongoing
costs
of
investing
in
the
fund
with
other
funds
by
contrasting
this
5%
hypothetical
example
and
the
5%
hypothetical
examples
that
appear
in
the
shareholder
reports
of
the
other
funds.
The
hypothetical
account
values
and
expenses
may
not
be
used
to
estimate
the
actual
ending
account
balance
or
expenses
you
paid
for
the
period.
You
should
also
be
aware
that
the
expenses
shown
in
the
table
highlight
only
your
ongoing
costs
and
do
not
reflect
any
transaction
costs,
such
as
redemption
fees
or
sales
loads.
Therefore,
the
second
line
of
the
table
is
useful
in
comparing
ongoing
costs
only
and
will
not
help
you
determine
the
relative
total
costs
of
owning
different
funds.
To
the
extent
a
fund
charges
transaction
costs,
however,
the
total
cost
of
owning
that
fund
is
higher.
Periods
Ended
12/31/22
1
Year
5
Years
10
Years
Institutional
Small-Cap
Stock
Fund
-23.31‌%
7.77‌%
11.24‌%
The
fund’s
performance
information
represents
only
past
performance
and
is
not
necessarily
an
indication
of
future
results.
Current
performance
may
be
lower
or
higher
than
the
performance
data
cited.
Share
price,
principal
value,
and
return
will
vary,
and
you
may
have
a
gain
or
loss
when
you
sell
your
shares.
For
the
most
recent
month-end
performance,
please
contact
a
T.
Rowe
Price
representative
at
1-800-638-8790.
This
table
shows
how
the
fund
would
have
performed
each
year
if
its
actual
(or
cumulative)
returns
for
the
periods
shown
had
been
earned
at
a
constant
rate.
Average
annual
total
return
figures
include
changes
in
principal
value,
reinvested
dividends,
and
capital
gain
distributions.
Returns
do
not
reflect
taxes
that
the
shareholder
may
pay
on
distributions
or
the
redemption
of
shares.
When
assessing
performance,
investors
should
consider
both
short-
and
long-term
returns.  
Institutional
Small-Cap
Stock
Fund
0.66‌%
The
expense
ratio
shown
is
as
of
the
fund’s
most
recent
prospectus.
This
number
may
vary
from
the
expense
ratio
shown
elsewhere
in
this
report
because
it
is
based
on
a
different
time
period
and,
if
applicable,
includes
acquired
fund
fees
and
expenses
but
does
not
include
fee
or
expense
waivers.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
7
INSTITUTIONAL
SMALL-CAP
STOCK
FUND
Beginning
Account
Value
7/1/22
Ending
Account
Value
12/31/22
Expenses
Paid
During
Period*
7/1/22
to
12/31/22
Actual
$1,000.00
$1,019.50
$3.36
Hypothetical
(assumes
5%
return
before
expenses)
 1,000.00
  1,021.88
  3.36
*
Expenses
are
equal
to
the
fund’s
annualized
expense
ratio
for
the
6-month
period
(0.66%),
multiplied
by
the
average
account
value
over
the
period,
multiplied
by
the
number
of
days
in
the
most
recent
fiscal
half
year
(184),
and
divided
by
the
days
in
the
year
(365)
to
reflect
the
half-year
period.
FUND
EXPENSE
EXAMPLE
(CONTINUED)
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
Financial
Highlights
8
For
a
share
outstanding
throughout
each
period
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
..
Year
..
..
Ended
.
12/31/22
12/31/21
12/31/20
12/31/19
12/31/18
NET
ASSET
VALUE
Beginning
of
period
$
32.85‌
$
30.62‌
$
25.61‌
$
20.30‌
$
23.72‌
Investment
activities
Net
investment
income
(1)(2)
0.06‌
0.01‌
0.05‌
0.04‌
0.07‌
Net
realized
and
unrealized
gain/loss
(7.73‌)
5.02‌
6.35‌
6.84‌
(0.76‌)
Total
from
investment
activities
(7.67‌)
5.03‌
6.40‌
6.88‌
(0.69‌)
Distributions
Net
investment
income
(0.05‌)
(0.02‌)
(0.05‌)
(0.04‌)
(0.05‌)
Net
realized
gain
(1.23‌)
(2.78‌)
(1.34‌)
(1.53‌)
(2.68‌)
Total
distributions
(1.28‌)
(2.80‌)
(1.39‌)
(1.57‌)
(2.73‌)
NET
ASSET
VALUE
End
of
period
$
23.90‌
$
32.85‌
$
30.62‌
$
25.61‌
$
20.30‌
Ratios/Supplemental
Data
Total
return
(2)(3)
(23.31‌)%
16.77‌%
25.00‌%
33.96‌%
(3.07‌)%
Ratios
to
average
net
assets:
(2)
Gross
expenses
before
waivers/payments
by
Price
Associates
0.66‌%
0.66‌%
0.66‌%
0.66‌%
0.66‌%
Net
expenses
after
waivers/payments
by
Price
Associates
0.66‌%
0.66‌%
0.66‌%
0.66‌%
0.66‌%
Net
investment
income
0.21‌%
0.02‌%
0.19‌%
0.17‌%
0.26‌%
Portfolio
turnover
rate
25.1‌%
18.9‌%
22.6‌%
28.7‌%
39.8‌%
Net
assets,
end
of
period
(in
millions)
$
4,479‌
$
6,158‌
$
6,164‌
$
5,645‌
$
4,174‌
(1)
Per
share
amounts
calculated
using
average
shares
outstanding
method.
(2)
See
Note
6
for
details
of
expense-related
arrangements
with
Price
Associates.
(3)
Total
return
reflects
the
rate
that
an
investor
would
have
earned
on
an
investment
in
the
fund
during
each
period,
assuming
reinvestment
of
all
distributions,
and
payment
of
no
redemption
or
account
fees,
if
applicable.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
December
31,
2022
9
Portfolio
of
Investments
Shares
$
Value
(Cost
and
value
in
$000s)
COMMON
STOCKS
93.2%
COMMUNICATION
SERVICES
0.4%
Entertainment
0.1%
Cinemark
Holdings  (1)
596,951‌
5,170‌
5,170‌
Interactive
Media
&
Services
0.3%
Bumble,
Class
A  (1)
482,000‌
10,146‌
Vimeo  (1)
1,439,100‌
4,936‌
15,082‌
Total
Communication
Services
20,252‌
CONSUMER
DISCRETIONARY
9.9%
Automobiles
0.5%
Rivian
Automotive,
Class
A  (1)
1,252,329‌
23,080‌
23,080‌
Diversified
Consumer
Services
1.3%
Bright
Horizons
Family
Solutions  (1)
339,275‌
21,408‌
Clear
Secure,
Class
1,169,843‌
32,089‌
Rover
Group,
Acquisition
Date:
8/2/21,
Cost $—  (1)(2)
361,837‌
7‌
Strategic
Education 
37,600‌
2,945‌
56,449‌
Hotels,
Restaurants
&
Leisure
3.1%
BJ's
Restaurants  (1)
604,553‌
15,948‌
Chuy's
Holdings  (1)
567,229‌
16,053‌
Dutch
Bros,
Class
A  (1)
121,799‌
3,433‌
Fiesta
Restaurant
Group  (1)
1,084,076‌
7,968‌
Marriott
Vacations
Worldwide 
81,405‌
10,956‌
Papa
John's
International 
535,847‌
44,106‌
Red
Robin
Gourmet
Burgers  (1)
254,225‌
1,419‌
Red
Rock
Resorts,
Class
172,069‌
6,884‌
Ruth's
Hospitality
Group 
391,720‌
6,064‌
Torchys
Holdings,
Class
A,
Acquisition
Date:
11/13/20,
Cost $17,606  (1)(2)
(3)(4)
2,059,233‌
8,257‌
Wyndham
Hotels
&
Resorts 
218,200‌
15,560‌
136,648‌
Household
Durables
0.5%
Skyline
Champion  (1)
439,216‌
22,624‌
22,624‌
Internet
&
Direct
Marketing
Retail
0.4%
Farfetch,
Class
A  (1)
1,319,107‌
6,239‌
Xometry,
Class
A  (1)
360,454‌
11,618‌
17,857‌
Multiline
Retail
0.8%
Ollie's
Bargain
Outlet
Holdings  (1)
804,721‌
37,693‌
37,693‌
Specialty
Retail
2.7%
Burlington
Stores  (1)
265,548‌
53,843‌
Five
Below  (1)
89,395‌
15,811‌
Monro 
553,581‌
25,022‌
RH  (1)
36,605‌
9,780‌
Shares
$
Value
(Cost
and
value
in
$000s)
Warby
Parker,
Class
A  (1)
1,169,426‌
15,776‌
120,232‌
Textiles,
Apparel
&
Luxury
Goods
0.6%
Skechers
USA,
Class
A  (1)
620,371‌
26,025‌
26,025‌
Total
Consumer
Discretionary
440,608‌
CONSUMER
STAPLES
3.6%
Beverages
0.9%
Boston
Beer,
Class
A  (1)
114,927‌
37,871‌
37,871‌
Food
&
Staples
Retailing
0.0%
Fresh
Market,
EC  (1)(3)
263,887‌
—‌
—‌
Food
Products
2.0%
Cal-Maine
Foods 
79,431‌
4,325‌
Nomad
Foods  (1)
1,014,271‌
17,486‌
Post
Holdings  (1)
287,512‌
25,951‌
Post
Holdings
Partnering  (1)
412,390‌
4,147‌
Simply
Good
Foods  (1)
269,800‌
10,261‌
TreeHouse
Foods  (1)
262,403‌
12,957‌
Utz
Brands 
1,037,892‌
16,461‌
91,588‌
Personal
Products
0.7%
BellRing
Brands  (1)
1,167,413‌
29,932‌
29,932‌
Total
Consumer
Staples
159,391‌
ENERGY
4.8%
Energy
Equipment
&
Services
1.4%
Cactus,
Class
272,532‌
13,697‌
Liberty
Energy,
Class
1,561,120‌
24,994‌
NexTier
Oilfield
Solutions  (1)
2,429,808‌
22,451‌
61,142‌
Oil,
Gas
&
Consumable
Fuels
3.4%
Devon
Energy 
467,548‌
28,759‌
Diamondback
Energy 
273,501‌
37,409‌
Kimbell
Royalty
Partners 
253,707‌
4,237‌
Magnolia
Oil
&
Gas,
Class
1,878,075‌
44,041‌
Venture
Global
LNG,
Series
B,
Acquisition
Date:
3/8/18,
Cost $577  (1)(2)(3)
191‌
2,826‌
Venture
Global
LNG,
Series
C,
Acquisition
Date:
5/25/17
-
3/8/18,
Cost $8,412  (1)(2)(3)
2,319‌
34,310‌
151,582‌
Total
Energy
212,724‌
FINANCIALS
16.1%
Banks
8.5%
BankUnited 
727,451‌
24,712‌
Cadence
Bank 
802,900‌
19,800‌
CRB
Group,
Acquisition
Date:
4/14/22,
Cost $1,368  (1)(2)(3)
13,013‌
1,007‌
CrossFirst
Bankshares  (1)
666,962‌
8,277‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
10
Shares
$
Value
(Cost
and
value
in
$000s)
Dime
Community
Bancshares 
564,918‌
17,981‌
Dogwood
State
Bank,
Non-Voting
Shares,
Acquisition
Date:
5/6/19,
Cost $1,511  (1)(2)(3)
151,114‌
2,720‌
Dogwood
State
Bank,
Voting
Shares,
Acquisition
Date:
5/6/19,
Cost $742  (1)(2)(3)
74,220‌
1,336‌
Dogwood
State
Bank,
Warrants,
5/6/24,
Acquisition
Date:
5/6/19,
Cost $—  (1)(2)(3)
22,533‌
182‌
East
West
Bancorp 
447,699‌
29,503‌
Equity
Bancshares,
Class
342,800‌
11,199‌
FB
Financial 
570,679‌
20,624‌
First
Bancshares 
422,332‌
13,519‌
Five
Star
Bancorp 
345,502‌
9,411‌
Grasshopper
Bancorp,
Acquisition
Date:
10/12/18
-
5/2/19,
Cost $2,456  (1)(2)(3)
245,627‌
983‌
Grasshopper
Bancorp,
Warrants,
10/12/28,
Acquisition
Date:
10/12/18,
Cost $—  (1)(2)(3)
47,055‌
34‌
Heritage
Commerce 
1,368,894‌
17,796‌
Home
BancShares 
790,938‌
18,026‌
Live
Oak
Bancshares 
557,549‌
16,838‌
Origin
Bancorp 
490,639‌
18,006‌
Pacific
Premier
Bancorp 
555,147‌
17,520‌
Pinnacle
Financial
Partners 
334,198‌
24,530‌
Popular 
189,827‌
12,589‌
Signature
Bank 
225,977‌
26,037‌
SouthState 
296,097‌
22,610‌
Veritex
Holdings 
490,770‌
13,781‌
Western
Alliance
Bancorp 
547,061‌
32,583‌
381,604‌
Capital
Markets
1.6%
Cboe
Global
Markets 
222,533‌
27,921‌
P10,
Class
1,070,646‌
11,424‌
StepStone
Group,
Class
647,587‌
16,306‌
TMX
Group
(CAD) 
147,900‌
14,803‌
70,454‌
Consumer
Finance
0.6%
Encore
Capital
Group  (1)
249,598‌
11,966‌
PRA
Group  (1)
463,138‌
15,645‌
27,611‌
Diversified
Financial
Services
0.1%
Conyers
Park
III
Acquisition  (1)
598,438‌
5,943‌
5,943‌
Insurance
3.8%
Assurant 
261,551‌
32,710‌
Axis
Capital
Holdings 
637,294‌
34,522‌
First
American
Financial 
228,800‌
11,975‌
Hanover
Insurance
Group 
204,003‌
27,567‌
Kemper 
277,602‌
13,658‌
Selective
Insurance
Group 
570,595‌
50,561‌
170,993‌
Thrifts
&
Mortgage
Finance
1.5%
Blue
Foundry
Bancorp  (1)
367,500‌
4,722‌
Capitol
Federal
Financial 
893,710‌
7,731‌
Shares
$
Value
(Cost
and
value
in
$000s)
Essent
Group 
270,046‌
10,499‌
Kearny
Financial 
743,500‌
7,546‌
PennyMac
Financial
Services 
670,165‌
37,972‌
68,470‌
Total
Financials
725,075‌
HEALTH
CARE
16.6%
Biotechnology
7.6%
Abcam,
ADR  (1)
1,474,653‌
22,946‌
Agios
Pharmaceuticals  (1)
228,806‌
6,425‌
Apellis
Pharmaceuticals  (1)
532,195‌
27,520‌
Argenx,
ADR  (1)
116,471‌
44,123‌
Ascendis
Pharma,
ADR  (1)
266,137‌
32,503‌
Avid
Bioservices  (1)
858,843‌
11,826‌
Blueprint
Medicines  (1)
364,425‌
15,965‌
Cerevel
Therapeutics
Holdings  (1)
296,321‌
9,346‌
CRISPR
Therapeutics  (1)
120,244‌
4,888‌
Cytokinetics  (1)
103,000‌
4,719‌
Flame
Biosciences,
Acquisition
Date:
9/28/20,
Cost $1,212  (1)(2)(3)
185,000‌
849‌
Generation
Bio  (1)
497,579‌
1,955‌
Icosavax  (1)
369,879‌
2,937‌
Insmed  (1)
1,107,292‌
22,124‌
Intellia
Therapeutics  (1)
128,781‌
4,493‌
Ionis
Pharmaceuticals  (1)
349,900‌
13,216‌
Karuna
Therapeutics  (1)
86,640‌
17,025‌
Kura
Oncology  (1)
363,278‌
4,508‌
Kymera
Therapeutics  (1)
105,014‌
2,621‌
Monte
Rosa
Therapeutics  (1)
209,491‌
1,594‌
Morphic
Holding  (1)
133,376‌
3,568‌
MorphoSys,
ADR  (1)
1,166,813‌
4,177‌
Nkarta  (1)
437,610‌
2,621‌
Nurix
Therapeutics  (1)
93,042‌
1,022‌
Prometheus
Biosciences  (1)
140,770‌
15,485‌
Prothena  (1)
176,432‌
10,630‌
RAPT
Therapeutics  (1)
261,979‌
5,187‌
Relay
Therapeutics  (1)
243,827‌
3,643‌
Repare
Therapeutics  (1)
205,900‌
3,029‌
Replimune
Group  (1)
117,234‌
3,189‌
Scholar
Rock,
Warrants,
12/31/25,
Acquisition
Date:
6/17/22,
Cost $—  (1)
(2)
45,404‌
230‌
Scholar
Rock
Holding  (1)
565,180‌
5,115‌
Tenaya
Therapeutics  (1)
62,288‌
125‌
Ultragenyx
Pharmaceutical  (1)
94,431‌
4,375‌
Vaxcyte  (1)
112,260‌
5,383‌
Verve
Therapeutics  (1)
205,514‌
3,977‌
Xencor  (1)
411,058‌
10,704‌
Zentalis
Pharmaceuticals  (1)
229,568‌
4,623‌
338,666‌
Health
Care
Equipment
&
Supplies
3.4%
AtriCure (1)
286,585‌
12,719‌
CVRx  (1)
142,925‌
2,623‌
ICU
Medical  (1)
157,049‌
24,732‌
Masimo  (1)
128,100‌
18,952‌
Outset
Medical  (1)
789,251‌
20,379‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
11
Shares
$
Value
(Cost
and
value
in
$000s)
Pax
Labs,
Class
A,
Acquisition
Date:
4/18/19,
Cost $7,145  (1)(2)(3)
1,897,440‌
1,252‌
Penumbra  (1)
97,336‌
21,653‌
PROCEPT
BioRobotics  (1)
620,031‌
25,756‌
QuidelOrtho  (1)
263,618‌
22,584‌
150,650‌
Health
Care
Providers
&
Services
3.4%
Alignment
Healthcare  (1)
908,267‌
10,681‌
dentalcorp
Holdings
(CAD)  (1)
775,955‌
5,100‌
ModivCare  (1)
270,491‌
24,271‌
Molina
Healthcare  (1)
166,258‌
54,902‌
Option
Care
Health  (1)
722,620‌
21,744‌
Pennant
Group  (1)
366,888‌
4,028‌
Privia
Health
Group  (1)
671,268‌
15,245‌
U.S.
Physical
Therapy 
189,722‌
15,373‌
151,344‌
Health
Care
Technology
0.3%
Certara (1)
130,977‌
2,105‌
Definitive
Healthcare  (1)
286,056‌
3,144‌
Doximity,
Class
A  (1)
299,494‌
10,051‌
15,300‌
Life
Sciences
Tools
&
Services
1.3%
Adaptive
Biotechnologies  (1)
157,606‌
1,204‌
Bruker 
594,968‌
40,666‌
NeoGenomics  (1)
696,900‌
6,439‌
Olink
Holding,
ADR  (1)
341,544‌
8,669‌
Rapid
Micro
Biosystems,
Class
A  (1)
547,186‌
618‌
Seer  (1)
227,576‌
1,320‌
58,916‌
Pharmaceuticals
0.6%
Arvinas (1)
119,601‌
4,092‌
Catalent  (1)
424,071‌
19,087‌
Reata
Pharmaceuticals,
Class
A  (1)
114,381‌
4,345‌
27,524‌
Total
Health
Care
742,400‌
INDUSTRIALS
&
BUSINESS
SERVICES
14.3%
Aerospace
&
Defense
0.7%
Cadre
Holdings 
289,829‌
5,837‌
Parsons  (1)
576,800‌
26,677‌
32,514‌
Building
Products
0.7%
CSW
Industrials 
138,377‌
16,042‌
Gibraltar
Industries  (1)
346,482‌
15,897‌
31,939‌
Commercial
Services
&
Supplies
1.7%
IAA (1)
285,909‌
11,436‌
MSA
Safety 
40,035‌
5,773‌
Rentokil
Initial
(GBP) 
3,693,685‌
22,693‌
Stericycle  (1)
472,403‌
23,568‌
Tetra
Tech 
95,561‌
13,875‌
77,345‌
Shares
$
Value
(Cost
and
value
in
$000s)
Construction
&
Engineering
0.2%
WillScot
Mobile
Mini
Holdings  (1)
188,420‌
8,511‌
8,511‌
Electrical
Equipment
0.8%
AZZ 
599,519‌
24,101‌
Shoals
Technologies
Group,
Class
A  (1)
341,651‌
8,428‌
Thermon
Group
Holdings  (1)
261,400‌
5,249‌
37,778‌
Machinery
6.7%
Enerpac
Tool
Group 
1,061,667‌
27,020‌
EnPro
Industries 
87,600‌
9,521‌
Esab 
213,814‌
10,032‌
ESCO
Technologies 
317,924‌
27,831‌
Federal
Signal 
604,066‌
28,071‌
Graco 
325,350‌
21,883‌
Helios
Technologies 
332,885‌
18,122‌
Ingersoll
Rand 
1,070,385‌
55,928‌
John
Bean
Technologies 
200,139‌
18,279‌
Marel
(ISK) 
1,160,174‌
4,015‌
Mueller
Water
Products,
Class
1,380,201‌
14,851‌
RBC
Bearings  (1)
85,000‌
17,795‌
SPX
Technologies  (1)
476,518‌
31,283‌
Toro 
151,526‌
17,153‌
301,784‌
Professional
Services
1.1%
Booz
Allen
Hamilton
Holding 
108,537‌
11,344‌
Checkr,
Acquisition
Date:
6/29/18
-
12/2/19,
Cost $2,271  (1)(2)(3)
291,546‌
2,245‌
Clarivate  (1)
1,725,394‌
14,390‌
Huron
Consulting
Group  (1)
177,462‌
12,884‌
Legalzoom.com  (1)
517,136‌
4,002‌
Upwork  (1)
459,391‌
4,796‌
49,661‌
Road
&
Rail
0.9%
Landstar
System 
96,878‌
15,781‌
Saia  (1)
125,228‌
26,258‌
42,039‌
Trading
Companies
&
Distributors
1.5%
Air
Lease 
481,465‌
18,498‌
Rush
Enterprises,
Class
314,938‌
16,465‌
SiteOne
Landscape
Supply  (1)
258,623‌
30,342‌
65,305‌
Total
Industrials
&
Business
Services
646,876‌
INFORMATION
TECHNOLOGY
12.0%
Communications
Equipment
0.2%
Clearfield (1)
52,775‌
4,968‌
Infinera  (1)
462,754‌
3,119‌
8,087‌
Electronic
Equipment,
Instruments
&
Components
3.2%
CTS 
702,488‌
27,692‌
Littelfuse 
107,299‌
23,627‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
12
Shares
$
Value
(Cost
and
value
in
$000s)
Novanta  (1)
129,040‌
17,533‌
PAR
Technology  (1)
590,580‌
15,396‌
Teledyne
Technologies  (1)
125,692‌
50,266‌
Vontier 
555,700‌
10,742‌
145,256‌
IT
Services
1.7%
Payoneer
Global  (1)
3,413,602‌
18,672‌
ServiceTitan,
Acquisition
Date:
11/9/18
-
5/4/21,
Cost $620  (1)(2)(3)
12,795‌
804‌
SS&C
Technologies
Holdings 
516,200‌
26,873‌
Themis
Solutions,
Acquisition
Date:
4/14/21,
Cost $1,603  (1)(2)(3)
71,410‌
1,273‌
Toast,
Class
A  (1)
1,598,506‌
28,821‌
76,443‌
Semiconductors
&
Semiconductor
Equipment
2.3%
Credo
Technology
Group
Holding  (1)
528,000‌
7,027‌
Entegris 
492,603‌
32,310‌
Lattice
Semiconductor  (1)
946,792‌
61,428‌
100,765‌
Software
4.6%
Amplitude,
Class
A  (1)
523,700‌
6,326‌
Blackline  (1)
306,500‌
20,618‌
Ceridian
HCM
Holding  (1)
58,354‌
3,743‌
Clearwater
Analytics
Holdings,
Class
A  (1)
270,301‌
5,068‌
Descartes
Systems
Group  (1)
469,426‌
32,695‌
DoubleVerify
Holdings  (1)
1,224,896‌
26,899‌
Five9  (1)
407,759‌
27,671‌
Manhattan
Associates  (1)
174,179‌
21,145‌
nCino  (1)
110,660‌
2,926‌
Paycom
Software  (1)
31,430‌
9,753‌
Paycor
HCM  (1)
649,031‌
15,882‌
Socure,
Acquisition
Date:
12/22/21,
Cost $1,200  (1)(2)(3)
74,692‌
559‌
Workiva  (1)
362,507‌
30,440‌
203,725‌
Total
Information
Technology
534,276‌
MATERIALS
3.1%
Chemicals
1.8%
Element
Solutions 
2,491,488‌
45,320‌
HB
Fuller 
119,741‌
8,576‌
Quaker
Chemical 
148,387‌
24,766‌
78,662‌
Metals
&
Mining
1.1%
Constellium (1)
1,804,988‌
21,353‌
ERO
Copper
(CAD)  (1)
536,970‌
7,392‌
Franco-Nevada
(CAD) 
34,120‌
4,651‌
Haynes
International 
370,333‌
16,921‌
50,317‌
Paper
&
Forest
Products
0.2%
West
Fraser
Timber
(CAD) 
121,634‌
8,783‌
8,783‌
Total
Materials
137,762‌
Shares
$
Value
(Cost
and
value
in
$000s)
REAL
ESTATE
5.1%
Equity
Real
Estate
Investment
Trusts
3.4%
Community
Healthcare
Trust,
REIT 
232,998‌
8,341‌
CubeSmart,
REIT 
712,288‌
28,670‌
EastGroup
Properties,
REIT 
303,421‌
44,925‌
First
Industrial
Realty
Trust,
REIT 
132,645‌
6,401‌
Flagship
Communities
REIT 
241,575‌
3,805‌
Independence
Realty
Trust,
REIT 
999,016‌
16,843‌
Rexford
Industrial
Realty,
REIT 
550,599‌
30,085‌
Terreno
Realty,
REIT 
226,500‌
12,881‌
151,951‌
Real
Estate
Management
&
Development
1.7%
Altus
Group
(CAD) 
137,800‌
5,500‌
DigitalBridge
Group 
567,259‌
6,206‌
FirstService 
398,437‌
48,828‌
Tricon
Residential 
1,850,994‌
14,271‌
74,805‌
Total
Real
Estate
226,756‌
UTILITIES
3.8%
Electric
Utilities
0.9%
IDACORP 
291,819‌
31,473‌
MGE
Energy 
152,394‌
10,728‌
42,201‌
Gas
Utilities
1.6%
Chesapeake
Utilities 
245,630‌
29,029‌
ONE
Gas 
150,228‌
11,375‌
Southwest
Gas
Holdings 
492,775‌
30,493‌
70,897‌
Independent
Power
&
Renewable
Electricity
Producers
0.4%
NextEra
Energy
Partners 
262,258‌
18,382‌
18,382‌
Water
Utilities
0.9%
California
Water
Service
Group 
273,207‌
16,567‌
SJW
Group 
282,838‌
22,964‌
39,531‌
Total
Utilities
171,011‌
Total
Miscellaneous
Common
Stocks
 3.5%  (5)
158,274‌
Total
Common
Stocks
(Cost
$3,318,848)
4,175,405‌
CONVERTIBLE
PREFERRED
STOCKS
3.8%
CONSUMER
DISCRETIONARY
0.4%
Hotels,
Restaurants
&
Leisure
0.4%
Cava
Group,
Series
E,
Acquisition
Date:
6/23/20
-
3/26/21,
Cost $9,599  (1)(2)(3)
381,719‌
12,223‌
Cava
Group,
Series
F,
Acquisition
Date:
3/26/21,
Cost $7,556  (1)(2)(3)
200,801‌
6,430‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
13
Shares
$
Value
(Cost
and
value
in
$000s)
Torchys
Holdings,
Acquisition
Date:
11/13/20,
Cost $3,632  (1)(2)(3)(4)
404,324‌
1,621‌
20,274‌
Internet
&
Direct
Marketing
Retail
0.0%
1661,
Series
F,
Acquisition
Date:
5/28/21,
Cost $6,391  (1)(2)(3)
1,098,082‌
2,021‌
2,021‌
Total
Consumer
Discretionary
22,295‌
CONSUMER
STAPLES
0.4%
Food
Products
0.4%
Farmers
Business
Network,
Series
D,
Acquisition
Date:
11/3/17,
Cost $6,275  (1)(2)(3)
339,830‌
17,002‌
Total
Consumer
Staples
17,002‌
FINANCIALS
0.1%
Banks
0.1%
CRB
Group,
Acquisition
Date:
1/28/22,
Cost $4,795  (1)(2)(3)
45,609‌
3,528‌
Total
Financials
3,528‌
HEALTH
CARE
1.1%
Biotechnology
0.2%
Caris
Life
Sciences,
Series
C,
Acquisition
Date:
8/14/20,
Cost $2,356  (1)(2)(3)
853,615‌
5,617‌
Caris
Life
Sciences,
Series
D,
Acquisition
Date:
5/11/21,
Cost $4,729  (1)(2)(3)
583,832‌
3,841‌
9,458‌
Health
Care
Equipment
&
Supplies
0.1%
Kardium,
Series
D-6,
Acquisition
Date:
1/8/21,
Cost $2,939  (1)(2)(3)
2,892,844‌
2,939‌
2,939‌
Health
Care
Providers
&
Services
0.1%
Honor
Technology,
Series
D,
Acquisition
Date:
10/16/20,
Cost $5,009  (1)(2)(3)
2,080,305‌
4,785‌
4,785‌
Life
Sciences
Tools
&
Services
0.7%
Cleerly,
Series
C,
Acquisition
Date:
7/8/22,
Cost $2,524  (1)(2)(3)
214,212‌
2,524‌
Inscripta,
Series
E,
Acquisition
Date:
3/30/21,
Cost $3,365  (1)(2)(3)
381,143‌
2,127‌
National
Resilience,
Series
B,
Acquisition
Date:
10/23/20,
Cost $3,621  (1)(2)(3)
265,089‌
16,099‌
National
Resilience,
Series
C,
Acquisition
Date:
6/9/21,
Cost $6,907  (1)(2)(3)
155,519‌
9,444‌
30,194‌
Total
Health
Care
47,376‌
Shares
$
Value
(Cost
and
value
in
$000s)
INDUSTRIALS
&
BUSINESS
SERVICES
0.7%
Aerospace
&
Defense
0.2%
ABL
Space
Systems,
Series
B,
Acquisition
Date:
3/24/21,
Cost $3,410  (1)(2)(3)
75,721‌
3,174‌
Epirus,
Series
C-2,
Acquisition
Date:
1/28/22,
Cost $6,074  (1)(2)(3)
1,087,799‌
6,074‌
9,248‌
Air
Freight
&
Logistics
0.1%
FLEXE,
Series
C,
Acquisition
Date:
11/18/20,
Cost $2,725  (1)(2)(3)
223,990‌
4,568‌
FLEXE,
Series
D,
Acquisition
Date:
4/7/22,
Cost $1,607  (1)(2)(3)
78,800‌
1,607‌
6,175‌
Electrical
Equipment
0.1%
CELLINK,
Series
D,
Acquisition
Date:
1/20/22,
Cost $2,969  (1)(2)(3)
142,571‌
2,969‌
2,969‌
Professional
Services
0.2%
Checkr,
Series
C,
Acquisition
Date:
4/10/18,
Cost $1,791  (1)(2)(3)
393,660‌
3,031‌
Checkr,
Series
D,
Acquisition
Date:
9/6/19,
Cost $6,330  (1)(2)(3)
627,795‌
4,834‌
7,865‌
Road
&
Rail
0.1%
Convoy,
Series
C,
Acquisition
Date:
9/14/18,
Cost $3,999  (1)(2)(3)
563,190‌
2,917‌
Convoy,
Series
D,
Acquisition
Date:
10/30/19,
Cost $5,376  (1)(2)(3)
397,082‌
2,057‌
4,974‌
Total
Industrials
&
Business
Services
31,231‌
INFORMATION
TECHNOLOGY
0.8%
IT
Services
0.3%
Haul
Hub,
Series
B,
Acquisition
Date:
2/14/20
-
3/3/21,
Cost $2,376  (1)(2)(3)
162,965‌
3,075‌
Haul
Hub,
Series
C,
Acquisition
Date:
4/14/22,
Cost $959  (1)(2)(3)
50,834‌
959‌
ServiceTitan,
Series
A-1,
Acquisition
Date:
11/9/18,
Cost $5  (1)(2)(3)
185‌
12‌
ServiceTitan,
Series
D,
Acquisition
Date:
11/9/18,
Cost $2,387  (1)(2)(3)
90,775‌
5,702‌
ServiceTitan,
Series
F,
Acquisition
Date:
3/25/21,
Cost $577  (1)(2)(3)
5,381‌
338‌
Themis
Solutions,
Series
AA,
Acquisition
Date:
4/14/21,
Cost $361  (1)(2)(3)
16,080‌
287‌
Themis
Solutions,
Series
AB,
Acquisition
Date:
4/14/21,
Cost $36  (1)(2)(3)
1,600‌
28‌
Themis
Solutions,
Series
B,
Acquisition
Date:
4/14/21,
Cost $39  (1)(2)(3)
1,750‌
31‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
14
Shares
$
Value
(Cost
and
value
in
$000s)
Themis
Solutions,
Series
E,
Acquisition
Date:
4/14/21,
Cost $4,568  (1)(2)(3)
203,440‌
3,625‌
14,057‌
Software
0.5%
Nuro,
Series
C,
Acquisition
Date:
10/30/20
-
3/2/21,
Cost $6,214  (1)
(2)(3)
475,993‌
6,607‌
Nuro,
Series
D,
Acquisition
Date:
10/29/21,
Cost $3,216  (1)(2)(3)
154,275‌
2,141‌
SecurityScorecard,
Series
E,
Acquisition
Date:
3/5/21,
Cost $3,099  (1)(2)(3)
613,641‌
2,994‌
Seismic
Software,
Series
E,
Acquisition
Date:
12/13/18,
Cost $3,462  (1)(2)(3)
549,145‌
5,684‌
Seismic
Software,
Series
F,
Acquisition
Date:
9/25/20,
Cost $374  (1)(2)(3)
42,590‌
441‌
Socure,
Series
A,
Acquisition
Date:
12/22/21,
Cost $1,459  (1)(2)(3)
90,776‌
679‌
Socure,
Series
A-1,
Acquisition
Date:
12/22/21,
Cost $1,197  (1)(2)(3)
74,504‌
557‌
Socure,
Series
B,
Acquisition
Date:
12/22/21,
Cost $22  (1)(2)(3)
1,348‌
10‌
Socure,
Series
E,
Acquisition
Date:
10/27/21,
Cost $2,775  (1)(2)(3)
172,687‌
1,292‌
20,405‌
Total
Information
Technology
34,462‌
MATERIALS
0.3%
Chemicals
0.2%
Redwood
Materials,
Series
C,
Acquisition
Date:
5/28/21,
Cost $4,206  (1)(2)(3)
88,718‌
6,920‌
Sila
Nano,
Series
F,
Acquisition
Date:
1/7/21,
Cost $5,284  (1)(2)(3)
128,029‌
3,991‌
10,911‌
Metals
&
Mining
0.1%
Kobold
Metals,
Series
B-1,
Acquisition
Date:
1/10/22,
Cost $3,092  (1)(2)(3)
112,792‌
3,092‌
3,092‌
Total
Materials
14,003‌
Total
Convertible
Preferred
Stocks
(Cost
$149,687)
169,897‌
SHORT-TERM
INVESTMENTS
3.0%
Money
Market
Funds
3.0%
T.
Rowe
Price
Government
Reserve
Fund,
4.30%  (6)(7)
134,889,277‌
134,889‌
Total
Short-Term
Investments
(Cost
$134,889)
134,889‌
Total
Investments
in
Securities
100.0%
of
Net
Assets
(Cost
$3,603,424)
$
4,480,191‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
15
Shares
are
denominated
in
U.S.
dollars
unless
otherwise
noted.
(1)
Non-income
producing
(2)
Security
cannot
be
offered
for
public
resale
without
first
being
registered
under
the
Securities
Act
of
1933
and
related
rules
("restricted
security").
Acquisition
date
represents
the
day
on
which
an
enforceable
right
to
acquire
such
security
is
obtained
and
is
presented
along
with
related
cost
in
the
security
description.
The
fund
may
have
registration
rights
for
certain
restricted
securities.
Any
costs
related
to
such
registration
are
generally
borne
by
the
issuer.
The
aggregate
value
of
restricted
securities
(excluding
144A
holdings)
at
period
end
amounts
to
$228,771
and
represents
5.1%
of
net
assets.
(3)
See
Note
2.
Level
3
in
fair
value
hierarchy.
(4)
Investment
in
a
partnership
held
indirectly
through
a
limited
liability
company
that
is
owned
by
the
fund
and
treated
as
a
corporation
for
U.S.
tax
purposes.
(5)
The
identity
of
certain
securities
has
been
concealed
to
protect
the
fund
while
it
completes
a
purchase
or
selling
program
for
the
securities.
(6)
Seven-day
yield
(7)
Affiliated
Companies
ADR
American
Depositary
Receipts
CAD
Canadian
Dollar
EC
Escrow
CUSIP;
represents
a
beneficial
interest
in
a
residual
pool
of
assets;
the
amount
and
timing
of
future
distributions,
if
any,
is
uncertain;
when
presented,
interest
rate
and
maturity
date
are
those
of
the
original
security.
GBP
British
Pound
ISK
Iceland
Krona
REIT
A
domestic
Real
Estate
Investment
Trust
whose
distributions
pass-through
with
original
tax
character
to
the
shareholder
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
16
yes
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
AFFILIATED
COMPANIES
($000s)
The
fund
may
invest
in
certain
securities
that
are
considered
affiliated
companies.
As
defined
by
the
1940
Act,
an
affiliated
company
is
one
in
which
the
fund
owns
5%
or
more
of
the
outstanding
voting
securities,
or
a
company
that
is
under
common
ownership
or
control.
The
following
securities
were
considered
affiliated
companies
for
all
or
some
portion
of
the
year
ended
December
31,
2022.
Net
realized
gain
(loss),
investment
income,
change
in
net
unrealized
gain/loss,
and
purchase
and
sales
cost
reflect
all
activity
for
the
period
then
ended.
Affiliate
Net
Realized
Gain
(Loss)
Change
in
Net
Unrealized
Gain/Loss
Investment
Income
T.
Rowe
Price
Government
Reserve
Fund,
4.30%
$
—‌
$
—‌
$
2,314‌++
Totals
$
—‌#
$
—‌
$
2,314‌+
Supplementary
Investment
Schedule
Affiliate
Value
12/31/21
Purchase
Cost
Sales
Cost
Value
12/31/22
T.
Rowe
Price
Government
Reserve
Fund,
4.30%
$
86,214‌
 ¤
  ¤
$
134,889‌
Total
$
134,889‌^
#
Capital
gain
distributions
from
underlying
Price
funds
represented
$0
of
the
net
realized
gain
(loss).
++
Excludes
earnings
on
securities
lending
collateral,
which
are
subject
to
rebates
and
fees
as
described
in
Note
3
.
+
Investment
income
comprised
$2,314
of
dividend
income
and
$0
of
interest
income.
¤
Purchase
and
sale
information
not
shown
for
cash
management
funds.
^
The
cost
basis
of
investments
in
affiliated
companies
was
$134,889.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
December
31,
2022
Statement
of
Assets
and
Liabilities
17
($000s,
except
shares
and
per
share
amounts)
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
Assets
Investments
in
securities,
at
value
(cost
$3,603,424)
$
4,480,191‌
Receivable
for
shares
sold
2,904‌
Dividends
receivable
2,461‌
Receivable
for
investment
securities
sold
12‌
Other
assets
715‌
Total
assets
4,486,283‌
Liabilities
Payable
for
shares
redeemed
4,742‌
Investment
management
fees
payable
2,534‌
Due
to
affiliates
6‌
Payable
to
directors
3‌
Other
liabilities
143‌
Total
liabilities
7,428‌
NET
ASSETS
$
4,478,855‌
Net
Assets
Consist
of:
Total
distributable
earnings
(loss)
$
910,415‌
Paid-in
capital
applicable
to
187,429,624
shares
of
$0.0001
par
value
capital
stock
outstanding;
2,000,000,000
shares
of
the
Corporation
authorized
3,568,440‌
NET
ASSETS
$
4,478,855‌
NET
ASSET
VALUE
PER
SHARE
$
23.90‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
Statement
of
Operations
18
($000s)
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
Year
Ended
12/31/22
Investment
Income
(Loss)
Dividend
(net
of
foreign
taxes
of
$271)
$
42,920‌
Securities
lending
4‌
Total
income
42,924‌
Expenses
Investment
management
32,208‌
Shareholder
servicing
6‌
Prospectus
and
shareholder
reports
68‌
Custody
and
accounting
301‌
Legal
and
audit
89‌
Registration
41‌
Directors
13‌
Miscellaneous
46‌
Total
expenses
32,772‌
Net
investment
income
10,152‌
Realized
and
Unrealized
Gain
/
Loss
Net
realized
gain
(loss)
Securities
218,757‌
Foreign
currency
transactions
(50‌)
Net
realized
gain
218,707‌
Change
in
net
unrealized
loss
on
securities
(1,654,215‌)
Net
realized
and
unrealized
gain
/
loss
(1,435,508‌)
DECREASE
IN
NET
ASSETS
FROM
OPERATIONS
$
(1,425,356‌)
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
Statement
of
Changes
in
Net
Assets
19
($000s)
The
accompanying
notes
are
an
integral
part
of
these
financial
statements.
Year
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Ended
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
12/31/22
12/31/21
Increase
(Decrease)
in
Net
Assets
Operations
Net
investment
income
$
10,152‌
$
1,619‌
Net
realized
gain
218,707‌
892,127‌
Change
in
net
unrealized
gain
/
loss
(1,654,215‌)
118,169‌
Increase
(decrease)
in
net
assets
from
operations
(1,425,356‌)
1,011,915‌
Distributions
to
shareholders
Net
earnings
(228,755‌)
(483,465‌)
Capital
share
transactions
*
Shares
sold
310,831‌
770,634‌
Distributions
reinvested
228,673‌
483,243‌
Shares
redeemed
(564,639‌)
(1,788,078‌)
Decrease
in
net
assets
from
capital
share
transactions
(25,135‌)
(534,201‌)
Net
Assets
Decrease
during
period
(1,679,246‌)
(5,751‌)
Beginning
of
period
6,158,101‌
6,163,852‌
End
of
period
$
4,478,855‌
$
6,158,101‌
*Share
information
(000s)
Shares
sold
11,255‌
22,777‌
Distributions
reinvested
9,637‌
15,268‌
Shares
redeemed
(20,905‌)
(51,891‌)
Decrease
in
shares
outstanding
(13‌)
(13,846‌)
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
20
NOTES
TO
FINANCIAL
STATEMENTS
T.
Rowe
Price
Equity
Funds,
Inc.
(the
corporation) is
registered
under
the
Investment
Company
Act
of
1940
(the
1940
Act).
The
Institutional
Small-Cap
Stock
Fund
(the
fund)
is a
diversified,
open-end
management
investment
company
established
by
the
corporation. The
fund
seeks
to
provide
long-term
capital
growth
by
investing
primarily
in
stocks
of
small
companies.
NOTE
1
-
SIGNIFICANT
ACCOUNTING
POLICIES 
Basis
of
Preparation
 The fund
is
an
investment
company
and
follows
accounting
and
reporting
guidance
in
the
Financial
Accounting
Standards
Board
(FASB)
Accounting
Standards
Codification
Topic
946
(ASC
946).
The
accompanying
financial
statements
were
prepared
in
accordance
with
accounting
principles
generally
accepted
in
the
United
States
of
America
(GAAP),
including,
but
not
limited
to,
ASC
946.
GAAP
requires
the
use
of
estimates
made
by
management.
Management
believes
that
estimates
and
valuations
are
appropriate;
however,
actual
results
may
differ
from
those
estimates,
and
the
valuations
reflected
in
the
accompanying
financial
statements
may
differ
from
the
value
ultimately
realized
upon
sale
or
maturity.
Investment
Transactions,
Investment
Income,
and
Distributions
Investment
transactions
are
accounted
for
on
the
trade
date
basis.
Income
and
expenses
are
recorded
on
the
accrual
basis.
Realized
gains
and
losses
are
reported
on
the
identified
cost
basis.
Income
tax-related
interest
and
penalties,
if
incurred,
are
recorded
as
income
tax
expense.
Dividends
received
from
mutual
fund
investments
are
reflected
as
dividend
income;
capital
gain
distributions
are
reflected
as
realized
gain/loss.
Dividend
income
and
capital
gain
distributions
are
recorded
on
the
ex-dividend
date.
Earnings
on
investments
recognized
as
partnerships
for
federal
income
tax
purposes
reflect
the
tax
character
of
such
earnings.
Distributions
from
REITs
are
initially
recorded
as
dividend
income
and,
to
the
extent
such
represent
a
return
of
capital
or
capital
gain
for
tax
purposes,
are
reclassified
when
such
information
becomes
available.
Non-cash
dividends,
if
any,
are
recorded
at
the
fair
market
value
of
the
asset
received.
Proceeds
from
litigation
payments,
if
any,
are
included
in
either
net
realized
gain
(loss)
or
change
in
net
unrealized
gain/loss
from
securities.
Distributions
to
shareholders
are
recorded
on
the
ex-dividend
date.
Income
distributions,
if
any,
are
declared
and
paid annually.
A
capital
gain
distribution,
if
any, may
also
be
declared
and
paid
by
the
fund
annually.
Currency
Translation
 Assets,
including
investments,
and
liabilities
denominated
in
foreign
currencies
are
translated
into
U.S.
dollar
values
each
day
at
the
prevailing
exchange
rate,
using
the
mean
of
the
bid
and
asked
prices
of
such
currencies
against
U.S.
dollars
as
provided
by
an
outside
pricing
service.
Purchases
and
sales
of
securities,
income,
and
expenses
are
translated
into
U.S.
dollars
at
the
prevailing
exchange
rate
on
the
respective
date
of
such
transaction.
The
effect
of
changes
in
foreign
currency
exchange
rates
on
realized
and
unrealized
security
gains
and
losses
is
not
bifurcated
from
the
portion
attributable
to
changes
in
market
prices.
In-Kind
Subscriptions
 Under
certain
circumstances,
and
when
considered
to
be
in
the
best
interest
of
all
shareholders,
the
fund
may
accept
portfolio
securities
rather
than
cash
as
payment
for
the
purchase
of
fund
shares
(in-kind
subscription).
For
financial
reporting
and
tax
purposes,
the
cost
basis
of
contributed
securities
is
equal
to
the
market
value
of
the
securities
on
the
date
of
contribution.
In-kind
subscriptions
result
in
no
gain
or
loss
and
no
tax
consequences
for
the
fund.
During
the
year ended
December
31,
2022,
the
fund
accepted
$20,089,000
of
in-kind
subscriptions,
all
of
which
were
from
other
T.
Rowe
Price
funds.
Capital
Transactions
 Each
investor’s
interest
in
the
net
assets
of the
fund
is
represented
by
fund
shares. The
fund’s
net
asset
value
(NAV)
per
share
is
computed
at
the
close
of
the
New
York
Stock
Exchange
(NYSE),
normally
4
p.m.
ET,
each
day
the
NYSE
is
open
for
business.
However,
the
NAV
per
share
may
be
calculated
at
a
time
other
than
the
normal
close
of
the
NYSE
if
trading
on
the
NYSE
is
restricted,
if
the
NYSE
closes
earlier,
or
as
may
be
permitted
by
the
SEC.
Purchases
and
redemptions
of
fund
shares
are
transacted
at
the
next-computed
NAV
per
share,
after
receipt
of
the
transaction
order
by
T.
Rowe
Price
Associates,
Inc.,
or
its
agents.
New
Accounting
Guidance
 In
June
2022,
the
FASB
issued
Accounting
Standards
Update
(ASU),
ASU
2022-03,
Fair
Value
Measurement
(Topic
820)
Fair
Value
Measurement
of
Equity
Securities
Subject
to
Contractual
Sale
Restrictions,
which
clarifies
that
a
contractual
restriction
on
the
sale
of
an
equity
security
is
not
considered
part
of
the
unit
of
account
of
the
equity
security
and,
therefore,
is
not
considered
in
measuring
fair
value.
The
amendments
under
this
ASU
are
effective
for
fiscal
years
beginning
after
December
15,
2023;
however,
the
fund
opted
to
early
adopt,
as
permitted,
effective
December
1,
2022. Adoption
of
the
guidance
did not
have
a
material
impact
on
the fund's
financial statements.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
21
Indemnification
 In
the
normal
course
of
business, the
fund
may
provide
indemnification
in
connection
with
its
officers
and
directors,
service
providers,
and/or
private
company
investments. The
fund’s
maximum
exposure
under
these
arrangements
is
unknown;
however,
the
risk
of
material
loss
is
currently
considered
to
be
remote.
NOTE
2
-
VALUATION 
Fair
Value
  The
fund’s
financial
instruments
are
valued
at
the
close
of
the
NYSE
and
are
reported
at
fair
value,
which
GAAP
defines
as
the
price
that
would
be
received
to
sell
an
asset
or
paid
to
transfer
a
liability
in
an
orderly
transaction
between
market
participants
at
the
measurement
date. The fund’s
Board
of
Directors
(the
Board)
has
designated
T.
Rowe
Price
Associates,
Inc.
as
the
fund’s
valuation
designee
(Valuation
Designee).
Subject
to
oversight
by
the
Board,
the
Valuation
Designee
performs
the
following
functions
in
performing
fair
value
determinations:
assesses
and
manages
valuation
risks;
establishes
and
applies
fair
value
methodologies;
tests
fair
value
methodologies;
and
evaluates
pricing
vendors
and
pricing
agents.
The
duties
and
responsibilities
of
the
Valuation
Designee
are
performed
by
its
Valuation
Committee. The
Valuation
Designee provides
periodic
reporting
to
the
Board
on
valuation
matters.
Various
valuation
techniques
and
inputs
are
used
to
determine
the
fair
value
of
financial
instruments.
GAAP
establishes
the
following
fair
value
hierarchy
that
categorizes
the
inputs
used
to
measure
fair
value:
Level
1
quoted
prices
(unadjusted)
in
active
markets
for
identical
financial
instruments
that
the
fund
can
access
at
the
reporting
date
Level
2
inputs
other
than
Level
1
quoted
prices
that
are
observable,
either
directly
or
indirectly
(including,
but
not
limited
to,
quoted
prices
for
similar
financial
instruments
in
active
markets,
quoted
prices
for
identical
or
similar
financial
instruments
in
inactive
markets,
interest
rates
and
yield
curves,
implied
volatilities,
and
credit
spreads)
Level
3
unobservable
inputs
(including
the Valuation
Designee’s assumptions
in
determining
fair
value)
Observable
inputs
are
developed
using
market
data,
such
as
publicly
available
information
about
actual
events
or
transactions,
and
reflect
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
Unobservable
inputs
are
those
for
which
market
data
are
not
available
and
are
developed
using
the
best
information
available
about
the
assumptions
that
market
participants
would
use
to
price
the
financial
instrument.
GAAP
requires
valuation
techniques
to
maximize
the
use
of
relevant
observable
inputs
and
minimize
the
use
of
unobservable
inputs.
When
multiple
inputs
are
used
to
derive
fair
value,
the
financial
instrument
is
assigned
to
the
level
within
the
fair
value
hierarchy
based
on
the
lowest-level
input
that
is
significant
to
the
fair
value
of
the
financial
instrument.
Input
levels
are
not
necessarily
an
indication
of
the
risk
or
liquidity
associated
with
financial
instruments
at
that
level
but
rather
the
degree
of
judgment
used
in
determining
those
values.
Valuation
Techniques 
Equity
securities,
including
exchange-traded
funds, listed
or
regularly
traded
on
a
securities
exchange
or
in
the
over-the-counter
(OTC)
market
are
valued
at
the
last
quoted
sale
price
or,
for
certain
markets,
the
official
closing
price
at
the
time
the
valuations
are
made.
OTC
Bulletin
Board
securities
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices.
A
security
that
is
listed
or
traded
on
more
than
one
exchange
is
valued
at
the
quotation
on
the
exchange
determined
to
be
the
primary
market
for
such
security.
Listed
securities
not
traded
on
a
particular
day
are
valued
at
the
mean
of
the
closing
bid
and
asked
prices
for
domestic
securities
and
the
last
quoted
sale
or
closing
price
for
international
securities.
The
last
quoted
prices
of
non-U.S.
equity
securities
may
be
adjusted
to
reflect
the
fair
value
of
such
securities
at
the
close
of
the
NYSE,
if
the Valuation
Designee
determines
that
developments
between
the
close
of
a
foreign
market
and
the
close
of
the
NYSE
will
affect
the
value
of
some
or
all
of the
fund’s
portfolio
securities.
Each
business
day,
the
Valuation
Designee uses
information
from
outside
pricing
services
to
evaluate
the
quoted
prices
of
portfolio
securities
and,
if
appropriate,
decide whether
it
is
necessary
to
adjust
quoted
prices
to
reflect
fair
value
by
reviewing
a
variety
of
factors,
including
developments
in
foreign
markets,
the
performance
of
U.S.
securities
markets,
and
the
performance
of
instruments
trading
in
U.S.
markets
that
represent
foreign
securities
and
baskets
of
foreign
securities. The Valuation
Designee
uses
outside
pricing
services
to
provide
it
with
quoted
prices
and
information
to
evaluate
or
adjust
those
prices.
The Valuation
Designee
cannot
predict
how
often
it
will
use
quoted
prices
and
how
often
it
will
determine
it
necessary
to
adjust
those
prices
to
reflect
fair
value.
Investments
in
mutual
funds
are
valued
at
the
mutual
fund’s
closing
NAV
per
share
on
the
day
of
valuation.
Assets
and
liabilities
other
than
financial
instruments,
including
short-term
receivables
and
payables,
are
carried
at
cost,
or
estimated
realizable
value,
if
less,
which
approximates
fair
value. 
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
22
Investments
for
which
market
quotations are
not
readily
available
or
deemed
unreliable
are
valued
at
fair
value
as
determined
in
good
faith
by
the
Valuation
Designee.
The
Valuation
Designee
has
adopted
methodologies
for
determining
the
fair
value
of
investments
for
which
market
quotations
are
not
readily
available
or
deemed
unreliable,
including
the
use
of
other
pricing
sources.
Factors
used
in
determining
fair
value
vary
by
type
of
investment
and
may
include
market
or
investment
specific
considerations.
The
Valuation
Designee typically
will
afford
greatest
weight
to
actual
prices
in
arm’s
length
transactions,
to
the
extent
they
represent
orderly
transactions
between
market
participants,
transaction
information
can
be
reliably
obtained,
and
prices
are
deemed
representative
of
fair
value.
However,
the
Valuation
Designee may
also
consider
other
valuation
methods
such
as
market-based
valuation
multiples;
a
discount
or
premium
from
market
value
of
a
similar,
freely
traded
security
of
the
same
issuer;
discounted
cash
flows;
yield
to
maturity;
or
some
combination.
Fair
value
determinations
are
reviewed
on
a
regular
basis.
Because
any
fair
value
determination
involves
a
significant
amount
of
judgment,
there
is
a
degree
of
subjectivity
inherent
in
such
pricing
decisions. Fair
value
prices
determined
by
the
Valuation
Designee could
differ
from
those
of
other
market
participants,
and
it
is
possible
that
the
fair
value
determined
for
a
security
may
be
materially
different
from
the
value
that
could
be
realized
upon
the
sale
of
that
security.
Valuation
Inputs
  The
following
table
summarizes
the
fund’s
financial
instruments,
based
on
the
inputs
used
to
determine
their
fair
values
on
December
31,
2022
(for
further
detail
by
category,
please
refer
to
the
accompanying
Portfolio
of
Investments):
Following
is
a
reconciliation
of
the
fund’s
Level
3
holdings
for
the
year ended
December
31,
2022.
Gain
(loss)
reflects
both
realized
and
change
in
unrealized
gain/loss
on
Level
3
holdings
during
the
period,
if
any,
and
is
included
on
the
accompanying
Statement
of
Operations.
The
change
in
unrealized
gain/loss
on
Level
3
instruments
held
at
December
31,
2022,
totaled $(54,565,000) for
the
year ended
December
31,
2022.
($000s)
Level
1
Level
2
Level
3
Total
Value
Assets
Common
Stocks
$
4,039,789‌
$
76,979‌
$
58,637‌
$
4,175,405‌
Convertible
Preferred
Stocks
—‌
—‌
169,897‌
169,897‌
Short-Term
Investments
134,889‌
—‌
—‌
134,889‌
Total
$
4,174,678‌
$
76,979‌
$
228,534‌
$
4,480,191‌
($000s)
Beginning
Balance
12/31/21
Gain
(Loss)
During
Period
Total
Purchases
Total
Sales
Ending
Balance
12/31/22
Investment
in
Securities
Common
Stocks
$
50,195‌
$
7,177‌
$
1,368‌
$
(103‌)
$
58,637‌
Convertible
Preferred
Stocks
209,637‌
(61,760‌)
22,020‌
—‌
169,897‌
Total
$
259,832‌
$
(54,583‌)
$
23,388‌
$
(103‌)
$
228,534‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
23
In
accordance
with
GAAP,
the
following
table
provides
quantitative
information
about
significant
unobservable
inputs
used
to
determine
the
fair
valuations
of
the
fund’s
Level
3
assets,
by
class
of
financial
instrument.
Because
the
Valuation
Designee considers
a
wide
variety
of
factors
and
inputs,
both
observable
and
unobservable,
in
determining
fair
values,
the
unobservable
inputs
presented
do
not
reflect
all
inputs
significant
to
the
fair
value
determination.
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Common
Stock
$58,637
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Discount
for
uncertainty
100%
100%
Decrease
Market
comparable
Enterprise
value
to
sales
multiple
1.5x
14.3x
3.6x
Increase
Sales
growth
rate
18%
168%
47%
Increase
Enterprise
value
to
gross
profit
multiple
6.0x
18.4x
10.9x
Increase
Gross
profit
growth
rate
21%
27%
23%
Increase
Enterprise
value
to
EBITDA
multiple
10.1x
26.9x
11.8x
Increase
EBITDA
growth
rate
23%
23%
Increase
Projected
enterprise
value
to
EBITDA
multiple
14.0x
14.0x
Increase
Price-to-earnings
multiple
8.4x
11.9x
10.3x
Increase
Price-to-earnings
growth
rate
0%
85%
43%
Increase
Probability
for
potential
outcome
20%
40%
30%
Decrease
Discount
rate
for
cost
of
capital
13%
13%
Decrease
Discount
for
lack
of
marketability
10%
10%
Decrease
Options
pricing
model
Private
company
valuation
—#
—#
—#
Risk-Free
rate
3%
4%
3%
Increase
Volatility
38%
55%
52%
Increase
Discount
for
lack
of
marketability
10%
10%
Decrease
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
24
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Convertible
Preferred
Stocks
$169,897
Recent
comparable
transaction
price(s)
—#
—#
—#
—#
Market
Comparable
Enterprise
value
to
sales
multiple
0.8x
14.3x
4.3x
Increase
Sales
growth
rate
18%
266%
42%
Increase
Enterprise
value
to
gross
profit
multiple
2.3x
18.4x
10.4x
Increase
Gross
profit
growth
rate
21%
57%
30%
Increase
Enterprise
value
to
EBITDA
multiple
8.4x
26.9x
21.1x
Increase
EBITDA
growth
rate
23%
312%
98%
Increase
Enterprise
value
to
gross
merchandise
value
multiple
0.5x
0.6x
0.6x
Increase
Gross
merchandise
value
growth
rate
30%
30%
Increase
Projected
enterprise
value
to
sales
multiple
0.8x
0.8x
Increase
Projected
enterprise
value
to
EBITDA
multiple
4.3x
4.3x
Increase
Price-to-earnings
multiple
8.4x
11.9x
10.3x
Increase
Price-to-earnings
growth
rate
0%
85%
43%
Increase
Discount
rate
for
cost
of
capital
30%
30%
Decrease
Discount
for
lack
of
marketability
10%
10%
Decrease
Options
pricing
model
Private
company
valuation
—#
—#
—#
Risk-Free
rate
4%
4%
Increase
Volatility
55%
55%
Increase
Discounted
cash
flow
Long-term
free
cash
flow
margin
27%
27%
Increase
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
25
+
Valuation
techniques
may
change
in
order
to
reflect the
Valuation
Designee’s
judgment
of
current
market
participant
assumptions. 
*
Unobservable
inputs
were
weighted
by
the
relative
fair
value
of
the
instruments.
**
Represents
the
directional
change
in
the
fair
value
of
the
Level
3
investment(s)
that
would
have
resulted
from
an
increase
in
the
corresponding
input
at
period
end.
A
decrease
in
the
unobservable
input
would
have
had
the
opposite
effect.
Significant
increases
and
decreases
in
these
inputs
in
isolation
could
result
in
significantly
higher
or
lower
fair
value
measurements.
#
No
quantitative
unobservable
inputs
significant
to
the
valuation
technique
were
created
by
the
Valuation
Designee.
NOTE
3
-
OTHER
INVESTMENT
TRANSACTIONS 
Consistent
with
its
investment
objective,
the
fund
engages
in
the
following
practices
to
manage
exposure
to
certain
risks
and/or
to
enhance
performance.
The
investment
objective,
policies,
program,
and
risk
factors
of
the
fund
are
described
more
fully
in
the
fund’s
prospectus
and
Statement
of
Additional
Information.
Restricted
Securities
 The
fund
invests
in
securities
that
are
subject
to
legal
or
contractual
restrictions
on
resale.
Prompt
sale
of
such
securities
at
an
acceptable
price
may
be
difficult
and
may
involve
substantial
delays
and
additional
costs.
Securities
Lending
 The fund
may
lend
its
securities
to
approved
borrowers
to
earn
additional
income.
Its
securities
lending
activities
are
administered
by
a
lending
agent
in
accordance
with
a
securities
lending
agreement.
Security
loans
generally
do
not
have
stated
maturity
dates,
and
the
fund
may
recall
a
security
at
any
time.
The
fund
receives
collateral
in
the
form
of
cash
or
U.S.
government
securities.
Collateral
is
maintained
over
the
life
of
the
loan
in
an
amount
not
less
than
the
value
of
loaned
securities;
any
additional
collateral
required
due
to
changes
in
security
values
is
delivered
to
the
fund
the
next
business
day.
Cash
collateral
is
invested
in
accordance
with
investment
guidelines
approved
by
fund
management.
Additionally,
the
lending
agent
indemnifies
the
fund
against
losses
resulting
from
borrower
default.
Although
risk
is
mitigated
by
the
collateral
and
indemnification,
the
fund
could
experience
a
delay
in
recovering
its
securities
and
a
possible
loss
of
income
or
value
if
the
borrower
fails
to
return
the
securities,
collateral
investments
decline
in
value,
and
the
lending
agent
fails
to
perform.
Securities
lending
revenue
consists
of
earnings
on
invested
collateral
and
borrowing
fees,
net
of
any
rebates
to
the
borrower,
compensation
to
the
lending
agent,
and
other
administrative
costs.
In
accordance
with
GAAP,
investments
made
with
cash
collateral
are
reflected
in
the
accompanying
financial
statements,
but
collateral
received
in
the
form
of
securities
is
not.
At
December
31,
2022,
there
were
no
securities
on
loan. 
Other 
Purchases
and
sales
of
portfolio
securities
other
than
short-term securities
aggregated $1,226,389,000 and
$1,516,260,000,
respectively,
for
the
year ended
December
31,
2022.
NOTE
4
-
FEDERAL
INCOME
TAXES
Generally,
no
provision
for
federal
income
taxes
is
required
since
the
fund
intends
to
continue
to
qualify
as
a
regulated
investment
company
under
Subchapter
M
of
the
Internal
Revenue
Code
and
distribute
to
shareholders
all
of
its
taxable
income
and
gains.
Distributions
determined
in
accordance
with
federal
income
tax
regulations
may
differ
in
amount
or
character
from
net
investment
income
and
realized
gains
for
financial
reporting
purposes.
The fund
files
U.S.
federal,
state,
and
local
tax
returns
as
required. The
fund’s
tax
returns
are
subject
to
examination
by
the
relevant
tax
authorities
until
expiration
of
the
applicable
statute
of
limitations,
which
is
generally
three
years
after
the
filing
of
the
tax
return
but
which
can
be
extended
to
six
years
in
certain
circumstances.
Tax
returns
for
open
years
have
incorporated
no
uncertain
tax
positions
that
require
a
provision
for
income
taxes.
Investments
in
Securities
Value
(000s)
Valuation
Technique(s)+
Significant
Unobservable
Input(s)
Value
or
Range
of
Input(s)
Weighted
Average
of
Input(s)*
Impact
to
Valuation
from
an
Increase
in
Input**
Long-term
free
cash
flow
growth
rate
3%
3%
Increase
Discount
rate
for
cost
of
capital
25%
25%
Decrease
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
26
Capital
accounts
within
the
financial
reporting
records
are
adjusted
for
permanent
book/tax
differences
to
reflect
tax
character
but
are
not
adjusted
for
temporary
differences.
The
permanent
book/tax
adjustments,
if
any,
have
no
impact
on
results
of
operations
or
net
assets.
The
permanent
book/tax
adjustments
relate
primarily
to
the
character
of
income
on
passive
foreign
investment
companies.
The
tax
character
of
distributions
paid
for
the
periods
presented
was
as
follows:
At
December
31,
2022,
the
tax-basis
cost
of
investments
(including
derivatives,
if
any)
and
gross
unrealized
appreciation
and
depreciation
were
as
follows:
At
December
31,
2022,
the
tax-basis
components
of
accumulated
net
earnings
(loss)
were
as
follows:
Temporary
differences
between
book-basis
and
tax-basis
components
of
total
distributable
earnings
(loss)
arise
when
certain
items
of
income,
gain,
or
loss
are
recognized
in
different
periods
for
financial
statement
purposes
versus
for
tax
purposes;
these
differences
will
reverse
in
a
subsequent
reporting
period.
The
temporary
differences
relate
primarily
to
the
deferral
of
losses
from
wash
sales.
NOTE
5
-
FOREIGN  TAXES
The
fund
is
subject
to
foreign
income
taxes
imposed
by
certain
countries
in
which
it
invests.
Additionally,
capital
gains
realized
upon
disposition
of
securities
issued
in
or
by
certain
foreign
countries
are
subject
to
capital
gains
tax
imposed
by
those
countries.
All
taxes
are
computed
in
accordance
with
the
applicable
foreign
tax
law,
and,
to
the
extent
permitted,
capital
losses
are
used
to
offset
capital
gains.
Taxes
attributable
to
income
are
accrued
by
the
fund
as
a
reduction
of
income.
Current
and
deferred
tax
expense
attributable
to
capital
gains
is
reflected
as
a
component
of
realized
or
change
in
unrealized
gain/loss
on
securities
in
the
accompanying
financial
statements.
To
the
extent
that
the
fund
has
country
specific
capital
loss
carryforwards,
such
carryforwards
are
applied
against
net
unrealized
gains
when
determining
the
deferred
tax
liability.
Any
deferred
tax
liability
incurred
by
the
fund
is
included
in
either
Other
liabilities
or
Deferred
tax
liability
on
the
accompanying
Statement
of
Assets
and
Liabilities.
($000s)
December
31,
2022
December
31,
2021
Ordinary
income
(including
short-term
capital
gains,
if
any)
$
13,171‌
$
70,793‌
Long-term
capital
gain
215,584‌
412,672‌
Total
distributions
$
228,755‌
$
483,465‌
($000s)
Cost
of
investments
$
3,613,135‌
Unrealized
appreciation
$
1,287,211‌
Unrealized
depreciation
(420,155‌)
Net
unrealized
appreciation
(depreciation)
$
867,056‌
($000s)
Undistributed
ordinary
income
$
57‌
Undistributed
long-term
capital
gain
43,302‌
Net
unrealized
appreciation
(depreciation)
867,056‌
Total
distributable
earnings
(loss)
$
910,415‌
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
27
NOTE
6
-
RELATED
PARTY
TRANSACTIONS
The
fund
is
managed
by
T.
Rowe
Price
Associates,
Inc.
(Price
Associates),
a
wholly
owned
subsidiary
of
T.
Rowe
Price
Group,
Inc.
(Price
Group). Price
Associates
has
entered
into
a
sub-advisory
agreement(s)
with
one
or
more
of
its
wholly
owned
subsidiaries,
to
provide
investment
advisory
services
to
the
fund. 
The
investment
management
agreement
between
the
fund
and
Price
Associates
provides
for
an
annual
investment
management
fee
equal
to 0.65%
of
the
fund’s
average
daily
net
assets.
The
fee
is
computed
daily
and
paid
monthly.
In
addition,
the
fund
has
entered
into
service
agreements
with
Price
Associates
and
a
wholly
owned
subsidiary
of
Price
Associates,
each
an
affiliate
of
the
fund
(collectively,
Price).
Price
Associates
provides
certain
accounting
and
administrative
services
to
the
fund.
T.
Rowe
Price
Services,
Inc.
provides
shareholder
and
administrative
services
in
its
capacity
as
the
fund’s
transfer
and
dividend-
disbursing
agent.
For
the
year ended
December
31,
2022,
expenses
incurred
pursuant
to
these
service
agreements
were
$102,000 for
Price
Associates
and $5,000
for
T.
Rowe
Price
Services,
Inc.
All
amounts
due
to
and
due
from
Price,
exclusive
of
investment
management
fees
payable,
are
presented
net
on
the
accompanying
Statement
of
Assets
and
Liabilities.
The fund
may
invest
its
cash
reserves
in
certain
open-end
management
investment
companies
managed
by
Price
Associates
and
considered
affiliates
of
the
fund:
the
T.
Rowe
Price
Government
Reserve
Fund
or
the
T.
Rowe
Price
Treasury
Reserve
Fund,
organized
as
money
market
funds
(together,
the
Price
Reserve
Funds).
The
Price
Reserve
Funds
are
offered
as
short-term
investment
options
to
mutual
funds,
trusts,
and
other
accounts
managed
by
Price
Associates
or
its
affiliates
and
are
not
available
for
direct
purchase
by
members
of
the
public.
Cash
collateral
from
securities
lending,
if
any,
is
invested
in
the
T.
Rowe
Price
Government
Reserve Fund. The
Price
Reserve
Funds
pay
no
investment
management
fees.
The
fund may
participate
in
securities
purchase
and
sale
transactions
with
other
funds
or
accounts
advised
by
Price
Associates
(cross
trades),
in
accordance
with
procedures
adopted
by the
fund’s
Board
and
Securities
and
Exchange
Commission
rules,
which
require,
among
other
things,
that
such
purchase
and
sale
cross
trades
be
effected
at
the
independent
current
market
price
of
the
security.
During
the
year ended
December
31,
2022,
the
fund
had
no
purchases
or
sales
cross
trades
with
other
funds
or
accounts
advised
by
Price
Associates.
Price
Associates
has
voluntarily
agreed
to
reimburse
the
fund
from
its
own
resources
on
a
monthly
basis
for
the
cost
of
investment
research
embedded
in
the
cost
of
the
fund’s
securities
trades
and
for
the
cost
of
brokerage
commissions
embedded
in
the
cost
of
the
fund’s
foreign
currency
transactions.
These
agreements
may
be
rescinded
at
any
time.
For
the
year ended
December
31,
2022,
these
reimbursements
amounted
to
$427,000,
which
is
included
in
Net
realized
gain
(loss)
on
Securities
in
the
Statement
of
Operations.
NOTE
7
-
OTHER
MATTERS
Unpredictable
events
such
as
environmental
or
natural
disasters,
war,
terrorism,
pandemics,
outbreaks
of
infectious
diseases,
and
similar
public
health
threats
may
significantly
affect
the
economy
and
the
markets
and
issuers
in
which
the fund
invests.
Certain
events
may
cause
instability
across
global
markets,
including
reduced
liquidity
and
disruptions
in
trading
markets,
while
some
events
may
affect
certain
geographic
regions,
countries,
sectors,
and
industries
more
significantly
than
others,
and
exacerbate
other
pre-existing
political,
social,
and
economic
risks.
Since
2020,
a
novel
strain
of
coronavirus
(COVID-19)
has
resulted
in
disruptions
to
global
business
activity
and
caused
significant
volatility
and
declines
in
global
financial
markets.
In
February
2022,
Russian
forces
entered
Ukraine
and
commenced
an
armed
conflict
leading
to
economic
sanctions
being
imposed
on
Russia
and
certain
of
its
citizens,
creating
impacts
on
Russian-related
stocks
and
debt
and
greater
volatility
in
global
markets.
These
are
recent
examples
of
global
events
which
may
have
a
negative
impact
on
the
values
of
certain
portfolio
holdings
or
the
fund’s
overall
performance.
Management
is
actively
monitoring
the
risks
and
financial
impacts
arising
from
these
events.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
28
Report
of
Independent
Registered
Public
Accounting
Firm
To
the
Board
of
Directors
of
T.
Rowe
Price
Equity
Funds,
Inc.
and
Shareholders
of
T.
Rowe
Price
Institutional
Small-Cap
Stock
Fund
Opinion
on
the
Financial
Statements
We
have
audited
the
accompanying
statement
of
assets
and
liabilities,
including
the
portfolio
of
investments,
of
T.
Rowe
Price
Institutional
Small-Cap
Stock
Fund
(one
of
the
funds
constituting
T.
Rowe
Price
Equity
Funds,
Inc.,
referred
to
hereafter
as
the
"Fund")
as
of
December
31,
2022,
the
related
statement
of
operations
for
the
year
ended
December
31,
2022,
the
statement
of
changes
in
net
assets
for
each
of
the
two
years
in
the
period
ended
December
31,
2022,
including
the
related
notes,
and
the
financial
highlights
for
each
of
the
five
years
in
the
period
ended
December
31,
2022
(collectively
referred
to
as
the
“financial
statements”).
In
our
opinion,
the
financial
statements
present
fairly,
in
all
material
respects,
the
financial
position
of
the
Fund
as
of
December
31,
2022,
the
results
of
its
operations
for
the
year
then
ended,
the
changes
in
its
net
assets
for
each
of
the
two
years
in
the
period
ended
December
31,
2022
and
the
financial
highlights
for
each
of
the
five
years
in
the
period
ended
December
31,
2022
in
conformity
with
accounting
principles
generally
accepted
in
the
United
States
of
America.
Basis
for
Opinion
These
financial
statements
are
the
responsibility
of
the
Fund’s
management.
Our
responsibility
is
to
express
an
opinion
on
the
Fund’s
financial
statements
based
on
our
audits.
We
are
a
public
accounting
firm
registered
with
the
Public
Company
Accounting
Oversight
Board
(United
States)
(PCAOB)
and
are
required
to
be
independent
with
respect
to
the
Fund
in
accordance
with
the
U.S.
federal
securities
laws
and
the
applicable
rules
and
regulations
of
the
Securities
and
Exchange
Commission
and
the
PCAOB.
We
conducted
our
audits
of
these
financial
statements
in
accordance
with
the
standards
of
the
PCAOB.
Those
standards
require
that
we
plan
and
perform
the
audit
to
obtain
reasonable
assurance
about
whether
the
financial
statements
are
free
of
material
misstatement,
whether
due
to
error
or
fraud.
Our
audits
included
performing
procedures
to
assess
the
risks
of
material
misstatement
of
the
financial
statements,
whether
due
to
error
or
fraud,
and
performing
procedures
that
respond
to
those
risks.
Such
procedures
included
examining,
on
a
test
basis,
evidence
regarding
the
amounts
and
disclosures
in
the
financial
statements.
Our
audits
also
included
evaluating
the
accounting
principles
used
and
significant
estimates
made
by
management,
as
well
as
evaluating
the
overall
presentation
of
the
financial
statements.
Our
procedures
included
confirmation
of
securities
owned
as
of
December
31,
2022
by
correspondence
with
the
custodians
and
transfer
agent.
We
believe
that
our
audits
provide
a
reasonable
basis
for
our
opinion.
PricewaterhouseCoopers
LLP
Baltimore,
Maryland
February
21,
2023
We
have
served
as
the
auditor
of
one
or
more
investment
companies
in
the
T.
Rowe
Price
group
of
investment
companies
since
1973.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
29
TAX
INFORMATION
(UNAUDITED)
FOR
THE
TAX
YEAR
ENDED 12/31/22
We
are
providing
this
information
as
required
by
the
Internal
Revenue
Code.
The
amounts
shown
may
differ
from
those
elsewhere
in
this
report
because
of
differences
between
tax
and
financial
reporting
requirements.
The
fund’s
distributions
to
shareholders
included:
$3,493,000 from
short-term
capital
gains 
$215,584,000 from
long-term
capital
gains,
subject
to
a
long-term
capital
gains
tax
rate
of
not
greater
than
20%
For
taxable
non-corporate
shareholders,
$9,678,000 of
the
fund's
income
represents
qualified
dividend
income
subject
to
a
long-term
capital
gains
tax
rate
of
not
greater
than
20%.
For
corporate
shareholders,
$9,678,000
of
the
fund's
income
qualifies
for
the
dividends-received
deduction.  
For
individuals
and
certain
trusts
and
estates
which
are
entitled
to
claim
a
deduction
of
up
to
20%
of
their
combined
qualified
real
estate
investment
trust
(REIT)
dividends,
$1,152,000 of
the
fund's
income
qualifies
as
qualified
real
estate
investment
trust
(REIT)
dividends.
INFORMATION
ON
PROXY
VOTING
POLICIES,
PROCEDURES,
AND
RECORDS
A
description
of
the
policies
and
procedures
used
by
T.
Rowe
Price
funds
to
determine
how
to
vote
proxies
relating
to
portfolio
securities
is
available
in
each
fund’s
Statement
of
Additional
Information.
You
may
request
this
document
by
calling
1-800-225-5132
or
by
accessing
the
SEC’s
website,
sec.gov.
The
description
of
our
proxy
voting
policies
and
procedures
is
also
available
on
our
corporate
website.
To
access
it,
please
visit
the
following
Web
page:
https://www.troweprice.com/corporate/us/en/utility/policies.html
Scroll
down
to
the
section
near
the
bottom
of
the
page
that
says,
“Proxy
Voting
Guidelines.”
Click
on
the
links
in
the
shaded
box.
Each
fund’s
most
recent
annual
proxy
voting
record
is
available
on
our
website
and
through
the
SEC’s
website.
To
access
it
through
T.
Rowe
Price,
visit
the
website
location
shown
above,
and
scroll
down
to
the
section
near
the
bottom
of
the
page
that
says,
“Proxy
Voting
Records.”
Click
on
the
Proxy
Voting
Records
link
in
the
shaded
box.
HOW
TO
OBTAIN
QUARTERLY
PORTFOLIO
HOLDINGS
The
fund
files
a
complete
schedule
of
portfolio
holdings
with
the
Securities
and
Exchange
Commission
(SEC)
for
the
first
and
third
quarters
of
each
fiscal
year
as
an
exhibit
to
its
reports
on
Form
N-PORT.
The
fund’s
reports
on
Form
N-PORT
are
available
electronically
on
the
SEC’s
website
(sec.gov).
In
addition,
most
T.
Rowe
Price
funds
disclose
their
first
and
third
fiscal
quarter-end
holdings
on
troweprice.com
.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
30
LIQUIDITY
RISK
MANAGEMENT
PROGRAM
In
accordance
with
Rule
22e-4
(Liquidity
Rule)
under
the
Investment
Company
Act
of
1940,
as
amended,
the
fund
has
established
a
liquidity
risk
management
program
(Liquidity
Program)
reasonably
designed
to
assess
and
manage
the
fund’s
liquidity
risk,
which
generally
represents
the
risk
that
the
fund
would
not
be
able
to
meet
redemption
requests
without
significant
dilution
of
remaining
investors’
interests
in
the
fund.
The
fund’s
Board
of
Directors
(Board)
has
appointed
the
fund’s
investment
adviser,
T.
Rowe
Price
Associates,
Inc.
(Adviser),
as
the
administrator
of
the
Liquidity
Program.
As
administrator,
the
Adviser
is
responsible
for
overseeing
the
day-to-day
operations
of
the
Liquidity
Program
and,
among
other
things,
is
responsible
for
assessing,
managing,
and
reviewing
with
the
Board
at
least
annually
the
liquidity
risk
of
each
T.
Rowe
Price
fund.
The
Adviser
has
delegated
oversight
of
the
Liquidity
Program
to
a
Liquidity
Risk
Committee
(LRC),
which
is
a
cross-
functional
committee
composed
of
personnel
from
multiple
departments
within
the
Adviser.
The
Liquidity
Program’s
principal
objectives
include
supporting
the
T.
Rowe
Price
funds’
compliance
with
limits
on
investments
in
illiquid
assets
and
mitigating
the
risk
that
the
fund
will
be
unable
to
timely
meet
its
redemption
obligations.
The
Liquidity
Program
also
includes
a
number
of
elements
that
support
the
management
and
assessment
of
liquidity
risk,
including
an
annual
assessment
of
factors
that
influence
the
fund’s
liquidity
and
the
periodic
classification
and
reclassification
of
a
fund’s
investments
into
categories
that
reflect
the
LRC’s
assessment
of
their
relative
liquidity
under
current
market
conditions.
Under
the
Liquidity
Program,
every
investment
held
by
the
fund
is
classified
at
least
monthly
into
one
of
four
liquidity
categories
based
on
estimations
of
the
investment’s
ability
to
be
sold
during
designated
time
frames
in
current
market
conditions
without
significantly
changing
the
investment’s
market
value.
As
required
by
the
Liquidity
Rule,
at
a
meeting
held
on
July
25,
2022,
the
Board
was
presented
with
an
annual
assessment
prepared
by
the
LRC,
on
behalf
of
the
Adviser,
that
addressed
the
operation
of
the
Liquidity
Program
and
assessed
its
adequacy
and
effectiveness
of
implementation,
including
any
material
changes
to
the
Liquidity
Program
and
the
determination
of
each
fund’s
Highly
Liquid
Investment
Minimum
(HLIM).
The
annual
assessment
included
consideration
of
the
following
factors,
as
applicable:
the
fund’s
investment
strategy
and
liquidity
of
portfolio
investments
during
normal
and
reasonably
foreseeable
stressed
conditions,
including
whether
the
investment
strategy
is
appropriate
for
an
open-end
fund,
the
extent
to
which
the
strategy
involves
a
relatively
concentrated
portfolio
or
large
positions
in
particular
issuers,
and
the
use
of
borrowings
for
investment
purposes
and
derivatives;
short-term
and
long-term
cash
flow
projections
covering
both
normal
and
reasonably
foreseeable
stressed
conditions;
and
holdings
of
cash
and
cash
equivalents,
as
well
as
available
borrowing
arrangements.
For
the
fund
and
other
T.
Rowe
Price
funds,
the
annual
assessment
incorporated
a
report
related
to
a
fund’s
holdings,
shareholder
and
portfolio
concentration,
any
borrowings
during
the
period,
cash
flow
projections,
and
other
relevant
data
for
the
period
of
April
1,
2021,
through
March
31,
2022.
The
report
described
the
methodology
for
classifying
a
fund’s
investments
(including
any
derivative
transactions)
into
one
of
four
liquidity
categories,
as
well
as
the
percentage
of
a
fund’s
investments
assigned
to
each
category.
It
also
explained
the
methodology
for
establishing
a
fund’s
HLIM
and
noted
that
the
LRC
reviews
the
HLIM
assigned
to
each
fund
no
less
frequently
than
annually.
During
the
period
covered
by
the
annual
assessment,
the
LRC
has
concluded,
and
reported
to
the
Board,
that
the
Liquidity
Program
continues
to
operate
adequately
and
effectively
and
is
reasonably
designed
to
assess
and
manage
the
fund’s
liquidity
risk.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
31
ABOUT
THE
FUND'S
DIRECTORS
AND
OFFICERS
Your
fund
is
overseen
by
a
Board
of
Directors
(Board)
that
meets
regularly
to
review
a
wide
variety
of
matters
affecting
or
potentially
affecting
the
fund,
including
performance,
investment
programs,
compliance
matters,
advisory
fees
and
expenses,
service
providers,
and
business
and
regulatory
affairs.
The
Board
elects
the
fund’s
officers,
who
are
listed
in
the
final
table.
The
directors
who
are
also
employees
or
officers
of
T.
Rowe
Price
are
considered
to
be
“interested”
directors
as
defined
in
Section
2(a)(19)
of
the
1940
Act
because
of
their
relationships
with
T.
Rowe
Price
and
its
affiliates.
The
business
address
of
each
director
and
officer
is
100
East
Pratt
Street,
Baltimore,
Maryland
21202.
The
Statement
of
Additional
Information
includes
additional
information
about
the
fund
directors
and
is
available
without
charge
by
calling
a
T.
Rowe
Price
representative
at
1-800-638-5660.
INDEPENDENT
DIRECTORS
(a)
INTERESTED  DIRECTORS
(a)
Name
(Year
of
Birth)
Year
Elected
[Number
of
T.
Rowe
Price
Portfolios
Overseen]
Principal
Occupation(s)
and
Directorships
of
Public
Companies
and
Other
Investment
Companies
During
the
Past
Five
Years
Teresa
Bryce
Bazemore
(1959)
2018
[205]
President
and
Chief
Executive
Officer,
Federal
Home
Loan
Bank
of
San
Francisco
(2021
to
present);
President,
Radian
Guaranty
(2008
to
2017);
Chief
Executive
Officer,
Bazemore
Consulting
LLC
(2018
to
2021);
Director,
Chimera
Investment
Corporation
(2017
to
2021);
Director,
First
Industrial
Realty
Trust
(2020
to
present);
Director,
Federal
Home
Loan
Bank
of
Pittsburgh
(2017
to
2019)
Ronald
J.
Daniels
(b)
(1959)
2018
[0]
President,
The
Johns
Hopkins
University
and
Professor,
Political
Science
Department,
The
Johns
Hopkins
University
(2009
to
present);
Director,
Lyndhurst
Holdings
(2015
to
present);
Director,
BridgeBio
Pharma,
Inc.
(2020
to
present)
Bruce
W.
Duncan
(1951)
2013
[205]
President,
Chief
Executive
Officer,
and
Director,
CyrusOne,
Inc.
(2020
to
2021);
Chief
Executive
Officer
and
Director
(2009
to
2016),
Chair
of
the
Board
(2016
to
2020),
and
President
(2009
to
2016),
First
Industrial
Realty
Trust,
owner
and
operator
of
industrial
properties;
Chair
of
the
Board
(2005
to
2016)
and
Director
(1999
to
2016),
Starwood
Hotels
&
Resorts,
a
hotel
and
leisure
company;
Member,
Investment
Company
Institute
Board
of
Governors
(2017
to
2019);
Member,
Independent
Directors
Council
Governing
Board
(2017
to
2019);
Senior
Advisor,
KKR
(2018
to
present);
Director,
Boston
Properties
(2016
to
present);
Director,
Marriott
International,
Inc.
(2016
to
2020)
Robert
J.
Gerrard,
Jr.
(1952)
2012
[205]
Advisory
Board
Member,
Pipeline
Crisis/Winning
Strategies,
a
collaborative
working
to
improve
opportunities
for
young
African
Americans
(1997
to
2016);
Chair
of
the
Board,
all
funds
(July
2018
to
present)
Paul
F.
McBride
(1956)
2013
[205]
Advisory
Board
Member,
Vizzia
Technologies
(2015
to
present);
Board
Member,
Dunbar
Armored
(2012
to
2018)
Kellye
L.
Walker
(c)
(1966)
2021
[205]
Executive
Vice
President
and
Chief
Legal
Officer,
Eastman
Chemical
Company
(April
2020
to
present);
Executive
Vice
President
and
Chief
Legal
Officer,
Huntington
Ingalls
Industries,
Inc.
(January
2015
to
March
2020);
Director,
Lincoln
Electric
Company
(October
2020
to
present)
(a)
All
information
about
the
independent
directors
was
current
as
of
December
31,
2021,
unless
otherwise
indicated,
except
for
the
number
of
portfolios
overseen,
which
is
current
as
of
the
date
of
this
report.
(b)
Effective
April
27,
2022,
Mr.
Daniels
resigned
from
his
role
as
an
independent
director
of
the
Price
Funds.
(c)
Effective
November
8,
2021,
Ms.
Walker
was
appointed
as
an
independent
director
of
the
Price
Funds.
Name
(Year
of
Birth)
Year
Elected
[Number
of
T.
Rowe
Price
Portfolios
Overseen]
Principal
Occupation(s)
and
Directorships
of
Public
Companies
and
Other
Investment
Companies
During
the
Past
Five
Years
David
Oestreicher
(1967)
2018
[205]
Director,
Vice
President,
and
Secretary,
T.
Rowe
Price,
T.
Rowe
Price
Investment
Services,
Inc.,
T.
Rowe
Price
Retirement
Plan
Services,
Inc.,
and
T.
Rowe
Price
Services,
Inc.;
Director
and
Secretary,
T.
Rowe
Price
Investment
Management,
Inc.
(Price
Investment
Management);
Vice
President
and
Secretary,
T.
Rowe
Price
International
(Price
International);
Vice
President,
T.
Rowe
Price
Hong
Kong
(Price
Hong
Kong),
T.
Rowe
Price
Japan
(Price
Japan),
and
T.
Rowe
Price
Singapore
(Price
Singapore);
General
Counsel,
Vice
President,
and
Secretary,
T.
Rowe
Price
Group,
Inc.;
Chair
of
the
Board,
Chief
Executive
Officer,
President,
and
Secretary,
T.
Rowe
Price
Trust
Company;
Principal
Executive
Officer
and
Executive
Vice
President,
all
funds
Robert
W.
Sharps,
CFA,
CPA
(b)
(1971)
2020
[0]
Director
and
Vice
President,
T.
Rowe
Price;
Director,
Price
Investment
Management;
Chief
Executive
Officer
and
President,
T.
Rowe
Price
Group,
Inc.;
Vice
President,
T.
Rowe
Price
Trust
Company
Eric
L.
Veiel,
CFA
(1972)
2022
[205]
Director
and
Vice
President,
T.
Rowe
Price;
Vice
President,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
(a)
All
information
about
the
interested
directors
was
current
as
of
January
1,
2022,
unless
otherwise
indicated,
except
for
the
number
of
portfolios
overseen,
which
is
current
as
of
the
date
of
this
report.
(b)
Effective
February
3,
2022,
Mr.
Sharps
resigned
from
his
role
as
an
interested
director
of
the
Price
Funds.
T.
ROWE
PRICE
Institutional
Small-Cap
Stock
Fund
32
OFFICERS
Name
(Year
of
Birth)
Position
Held
With Equity
Funds 
Principal
Occupation(s) 
Francisco Alonso
(1978)
Executive
Vice
President
Vice
President,
Price
Investment
Management,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
Brian
W.H.
Berghuis,
CFA
(1958)
Executive
Vice
President
Vice
President,
Price
Investment
Management,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
Armando
(Dino)
Capasso
(1974)
Chief
Compliance
Officer
Chief
Compliance
Officer
and
Vice
President,
T.
Rowe
Price
and
Price
Investment
Management;
Vice
President,
T.
Rowe
Price
Group,
Inc.;
formerly,
Chief
Compliance
Officer,
PGIM
Investments
LLC
and
AST
Investment
Services,
Inc.
(ASTIS)
(to
2022);
Chief
Compliance
Officer,
PGIM
Retail
Funds
complex
and
Prudential
Insurance
Funds
(to
2022);
Vice
President
and
Deputy
Chief
Compliance
Officer,
PGIM
Investments
LLC
and
ASTIS
(to
2019);
Senior
Vice
President
and
Senior
Counsel,
Pacific
Investment
Management
Company
LLC
(to
2017) 
Alan
S.
Dupski,
CPA
(1982)
Principal
Financial
Officer,
Vice
President,
and
Treasurer
Vice
President,
Price
Investment
Management,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
Gary
J.
Greb
(1961)
Vice
President
Vice
President,
Price
Investment
Management,
T.
Rowe
Price,
Price
International,
and
T.
Rowe
Price
Trust
Company
Paul
D.
Greene
II
(1978)
Executive
Vice
President
Vice
President,
T.
Rowe
Price
and
T.
Rowe
Price
Group,
Inc.
Cheryl
Hampton,
CPA
(1969)
Vice
President
Vice
President,
T.
Rowe
Price;
formerly,
Tax
Director,
Invesco
Ltd.
(to
2021);
Vice
President,
Oppenheimer
Funds,
Inc.
(to
2019)
Stephon
Jackson,
CFA
(1962)
Co-president 
Vice
President,
T.
Rowe
Price
Benjamin
Kersse,
CPA
(1989)
Vice
President
Vice
President,
T.
Rowe
Price
Paul
J.
Krug,
CPA
(1964)
Vice
President
Vice
President,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
John
D.
Linehan,
CFA
(1965)
Executive
Vice
President
Vice
President,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
Joshua
Nelson
(1977)
Co-president 
Vice
President,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
Price
International,
and
T.
Rowe
Price
Trust
Company
Fran
M.
Pollack-Matz
(1961)
Vice
President
and
Secretary 
Vice
President,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
T.
Rowe
Price
Investment
Services,
Inc.,
and
T.
Rowe
Price
Services,
Inc.
Shannon
H.
Rauser
(1987)
Assistant
Secretary 
Assistant
Vice
President,
T.
Rowe
Price
Gabriel
Solomon
(1977)
Executive
Vice
President
Vice
President,
T.
Rowe
Price
and
T.
Rowe
Price
Group,
Inc.
Taymour
R.
Tamaddon,
CFA
(1976)
Executive
Vice
President
Vice
President,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
and
T.
Rowe
Price
Trust
Company
John
F.
Wakeman
(1962)
Vice
President
Vice
President,
Price
Investment
Management
and
T.
Rowe
Price
Group,
Inc.
Megan
Warren
(1968)
Vice
President
OFAC
Sanctions
Compliance
Officer
and
Vice
President,
Price
Investment
Management;
Vice
President,
T.
Rowe
Price,
T.
Rowe
Price
Group,
Inc.,
T.
Rowe
Price
Retirement
Plan
Services,
Inc.,
T.
Rowe
Price
Services,
Inc.,
and
T.
Rowe
Price
Trust
Company
Unless
otherwise
noted,
officers
have
been
employees
of
T.
Rowe
Price
or
Price
International
for
at
least
5
years.
100
East
Pratt
Street
Baltimore,
MD
21202
T.
Rowe
Price
Investment
Services,
Inc.
Call
1-800-225-5132
to
request
a
prospectus
or
summary
prospectus;
each
includes
investment
objectives,
risks,
fees,
expenses,
and
other
information
that
you
should
read
and
consider
carefully
before
investing.
202302-2582688
E129-050
2/23


Item 1. (b) Notice pursuant to Rule 30e-3.

Not applicable.

Item 2.  Code of Ethics.

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics during the period covered by this report.

Item 3.  Audit Committee Financial Expert.

The registrant’s Board of Directors has determined that Ms. Teresa Bryce Bazemore qualifies as an audit committee financial expert, as defined in Item 3 of Form N-CSR. Ms. Bazemore is considered independent for purposes of Item 3 of Form N-CSR.

Item 4.  Principal Accountant Fees and Services.

(a) – (d)  Aggregate fees billed for the last two fiscal years for professional services rendered to, or on behalf of, the registrant by the registrant’s principal accountant were as follows:

 

               

2022

    

2021

 
 

Audit Fees

   $ 41,909      $ 40,759  
 

Audit-Related Fees

     -        -  
 

Tax Fees

     -        5,742  
 

All Other Fees

     -        -  

Audit fees include amounts related to the audit of the registrant’s annual financial statements and services normally provided by the accountant in connection with statutory and regulatory filings. Audit-related fees include amounts reasonably related to the performance of the audit of the registrant’s financial statements and specifically include the issuance of a report on internal controls and, if applicable, agreed-upon procedures related to fund acquisitions. Tax fees include amounts related to services for tax compliance, tax planning, and tax advice. The nature of these services specifically includes the review of distribution calculations and the preparation of Federal, state, and excise tax returns. All other fees include the registrant’s pro-rata share of amounts for agreed-upon procedures in conjunction with service contract approvals by the registrant’s Board of Directors/Trustees.

(e)(1)  The registrant’s audit committee has adopted a policy whereby audit and non-audit services performed by the registrant’s principal accountant for the registrant, its investment adviser, and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant require pre-approval in advance at regularly scheduled audit committee meetings. If such a service is required between regularly scheduled audit committee meetings, pre-approval may be authorized by one audit committee member with ratification at the next scheduled audit committee meeting. Waiver of pre-approval for audit or non-audit services requiring fees of a de minimis amount is not permitted.

(2)  No services included in (b) – (d) above were approved pursuant to paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

 


(f)  Less than 50 percent of the hours expended on the principal accountant’s engagement to audit the registrant’s financial statements for the most recent fiscal year were attributed to work performed by persons other than the principal accountant’s full-time, permanent employees.

(g)  The aggregate fees billed for the most recent fiscal year and the preceding fiscal year by the registrant’s principal accountant for non-audit services rendered to the registrant, its investment adviser, and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant were $2,037,000 and $3,732,000, respectively.

(h)  All non-audit services rendered in (g) above were pre-approved by the registrant’s audit committee. Accordingly, these services were considered by the registrant’s audit committee in maintaining the principal accountant’s independence.

Item 5.  Audit Committee of Listed Registrants.

Not applicable.

Item 6. Investments.

(a)  Not applicable. The complete schedule of investments is included in Item 1 of this Form N-CSR.

(b)  Not applicable.

Item 7.  Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.

Not applicable.

Item 8.  Portfolio Managers of Closed-End Management Investment Companies.

Not applicable.

Item 9.  Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.

Not applicable.

Item 10.  Submission of Matters to a Vote of Security Holders.

There has been no change to the procedures by which shareholders may recommend nominees to the registrant’s board of directors.

Item 11.  Controls and Procedures.

(a)  The registrant’s principal executive officer and principal financial officer have evaluated the registrant’s disclosure controls and procedures within 90 days of this filing and have concluded that the registrant’s disclosure controls and procedures were effective, as of that date, in ensuring that information required to be disclosed by the registrant in this Form N-CSR was recorded, processed, summarized, and reported timely.

 


(b)  The registrant’s principal executive officer and principal financial officer are aware of no change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 12. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.

Not applicable.

Item 13.   Exhibits.

(a)(1) The registrant’s code of ethics pursuant to Item 2 of Form N-CSR is attached.

    (2) Separate certifications by the registrant’s principal executive officer and principal financial officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2(a) under the Investment Company Act of 1940, are attached.

    (3) Written solicitation to repurchase securities issued by closed-end companies: not applicable.

(b) A certification by the registrant’s principal executive officer and principal financial officer, pursuant to Section  906 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2(b) under the Investment Company Act of 1940, is attached.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

T. Rowe Price Equity Funds, Inc.

By

 

/s/ David Oestreicher

 

David Oestreicher

 

Principal Executive Officer

Date

 

February 21, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

By

 

/s/ David Oestreicher

 

David Oestreicher

 

Principal Executive Officer

Date

 

February 21, 2023

By

 

/s/ Alan S. Dupski

 

Alan S. Dupski

 

Principal Financial Officer

Date

 

February 21, 2023

 
EX-99.CERT 2 d269721dex99cert.htm 302 CERTIFICATIONS 302 CERTIFICATIONS

Item 13. (a)(2)

CERTIFICATIONS

I, David Oestreicher, certify that:

 

1.

I have reviewed this report on Form N-CSR of T. Rowe Price Institutional Small-Cap Stock Fund;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 21, 2023

       /s/ David Oestreicher                        
      

David Oestreicher

      

Principal Executive Officer


CERTIFICATIONS

I, Alan S. Dupski, certify that:

 

1.

I have reviewed this report on Form N-CSR of T. Rowe Price Institutional Small-Cap Stock Fund;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

 

  (a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

 

  (d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

 

  (b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 21, 2023

       /s/ Alan S. Dupski                            
      

Alan S. Dupski

      

Principal Financial Officer

 

EX-99.906CE 3 d269721dex99906ce.htm 906 CERTIFICATIONS 906 CERTIFICATIONS

Item 13. (b)

CERTIFICATION UNDER SECTION 906 OF SARBANES-OXLEY ACT OF 2002

Name of Issuer: T. Rowe Price Institutional Small-Cap Stock Fund

In connection with the Report on Form N-CSR for the above named Issuer, the undersigned hereby certifies, to the best of his knowledge, that:

 

  1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934;

 

  2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Issuer.

 

Date: February 21, 2023

   

    

  

/s/ David Oestreicher

      

David Oestreicher

      

Principal Executive Officer

Date: February 21, 2023

      

/s/ Alan S. Dupski

      

Alan S. Dupski

      

Principal Financial Officer

EX-99.CODE ETH 4 d269721dex99codeeth.htm CODE OF ETHICS CODE OF ETHICS

CODE OF ETHICS FOR PRINCIPAL EXECUTIVE AND SENIOR FINANCIAL

OFFICERS OF THE T. ROWE PRICE MUTUAL FUNDS AND EXCHANGE-

TRADED FUNDS

UNDER THE SARBANES-OXLEY ACT OF 2002

I.  General Statement. This Code of Ethics for the T. Rowe Price Mutual Funds and Exchange-Traded Funds (the “Price ETFs” and, together with the Mutual Funds, the “Price Funds”) has been designed to bring the Price Funds into compliance with the applicable requirements of the Sarbanes-Oxley Act of 2002 (the “Act”) and rules promulgated by the Securities and Exchange Commission thereunder (“Regulations”). This Price Funds’ Code of Ethics (the “S-O Code”) applies solely to the Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer or Controller of, or persons performing similar functions for, a Price Fund (whether such persons are employed by a Price Fund or third party) (“Covered Officers”). The “Price Funds” shall include each mutual fund and ETF that is managed, sponsored and distributed by affiliates of T. Rowe Price Group, Inc. (“Group”). The investment managers to the Price Funds will be referred to as the “Price Fund Advisers.” A list of Covered Officers is attached as Exhibit A.

The Price Fund Advisers have, along with their parent, T. Rowe Price Group, Inc. (“Group”) also maintained a comprehensive Code of Ethics and Conduct (the “Group Code”) since 1972, which applies to all officers, directors and employees of the Price Funds, Group and its affiliates.

As mandated by the Act, Group has adopted a Code (the “Group S-O Code”), similar to the Price Funds S-O Code, which applies solely to its principal executive and senior financial officers. The Group S-O Code and the Price Funds S-O Code will be referred to collectively as the “S-O Codes”.

The Price Funds S-O Code has been adopted by the Price Funds in accordance with the Act and Regulations thereunder and will be administered in conformity with the disclosure requirements of Item 2 of Form N-CSR. The S-O Codes are attachments to the Group Code. In many respects the S-O Codes are supplementary to the Group Code, but the Group Code is administered separately from the S-O Codes, as the S-O Codes are from each other.

II.  Purpose of the Price Funds S-O Code. The purpose of the Price Funds S-O Code, as mandated by the Act and the Regulations, is to establish standards that are reasonably designed to deter wrongdoing and to promote:

Ethical Conduct. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships.

Disclosure. Full, fair, accurate, timely and understandable disclosure in reports and documents that the Price Funds file with, or submit to, the SEC and in other public communications made by the Price Funds.

Compliance. Compliance with applicable governmental laws, rules and regulations.

Reporting of Violations. The prompt internal reporting of violations of the Price Funds S-O Code to an appropriate person or persons identified in the Price Funds S-O Code.

Accountability. Accountability for adherence to the Price Funds S-O Code.

 

1


III.  Covered Officers Should Handle Ethically Actual and Apparent Conflicts of Interest.

Overview. Each Covered Officer owes a duty to the Price Funds to adhere to a high standard of honesty and business ethics and should be sensitive to situations that may give rise to actual as well as apparent conflicts of interest.

A “conflict of interest” occurs when a Covered Officer’s private interest interferes with the interests of, or his or her service to, the Price Funds. For example, a conflict of interest would arise if a Covered Officer, or a member of his or her family, receives improper personal benefits as a result of his or her position with a Price Fund.

Certain conflicts of interest covered by the Price Funds S-O Code arise out of the relationships between Covered Officers and the Price Funds and may already be subject to provisions regulating conflicts of interest in the Investment Company Act of 1940 (“Investment Company Act”), the Investment Advisers Act of 1940 (“Investment Advisers Act”) and the Group Code. For example, Covered Officers may not individually engage in certain transactions (such as the purchase or sale of securities or other property) with a Price Fund because of their status as “affiliated persons” of a Price Fund. The compliance programs and procedures of the Price Funds and Price Fund Advisers are designed to prevent, or identify and correct, violations of these provisions.

Although typically not presenting an opportunity for improper personal benefit, conflicts arise from, or as a result of, the contractual relationship between a Price Fund and its Price Fund Adviser (and its affiliates) of which the Covered Officers may also be officers or employees. As a result, the Price Funds S-O Code recognizes that the Covered Officers will, in the normal course of their duties (whether formally for the Price Funds or for the Price Fund Advisers, or for both), be involved in establishing policies and implementing decisions which will have different effects on these entities. The participation of the Covered Officers in such activities is inherent in the contractual relationship between each Price Fund and its respective Price Fund Adviser. Such participation is also consistent with the performance by the Covered Officers of their duties as officers of the Price Funds and, if consistent with the provisions of the Investment Company Act and the Investment Advisers Act, it will be deemed to have been handled ethically.

Other conflicts of interest are covered by the Price Funds and Price ETFs S-O Code, even if these conflicts of interest are not addressed by or subject to provisions in the Investment Company Act and the Investment Advisers Act.

Whenever a Covered Officer is confronted with a conflict of interest situation where he or she is uncertain as to the appropriate action to be taken, he or she should discuss the matter with the Chairperson of Group’s Ethics Committee or another member of the Committee.

Handling of Specific Types of Conflicts. Each Covered Officer (and close family members) must not:

Entertainment. Accept entertainment from any company with which any Price Fund or any Price Fund Adviser has current or prospective business dealings including portfolio companies, unless such entertainment is in full compliance with the policy on entertainment as set forth in the Group Code.

 

2


Gifts. Accept any gifts, except as permitted by the Group Code.

Improper Personal Influence. Use his or her personal influence or personal relationships improperly to influence investment decisions, brokerage allocations or financial reporting by the Price Funds to the detriment of any one or more of the Price Funds.

Taking Action at the Expense of a Price Fund. Cause a Price Fund to take action, or fail to take action, for the personal benefit of the Covered Officer rather than for the benefit of one or more of the Price Funds.

Misuse of Price Funds’ Transaction Information. Use knowledge of portfolio transactions made or contemplated for a Price Fund or any other clients of the Price Fund Advisers to trade personally or cause others to trade in order to take advantage of or avoid the market impact of such portfolio transactions; and in connection with Price ETFs that do not disclose portfolio holdings daily, use knowledge of pending changes to an ETF’s proxy portfolio holdings for such purposes.

Outside Business Activities. Engage in any outside business activity that detracts from a Covered Officer’s ability to devote appropriate time and attention to his or her responsibilities to a Price Fund.

Service Providers. Excluding Group and its affiliates, have any ownership interest in, or any consulting or employment relationship with, any of the Price Funds’ service providers, except that an ownership interest in public companies is permitted

Receipt of Payments. Have a direct or indirect financial interest in commissions, transaction charges, spreads or other payments paid by a Price Fund for effecting portfolio transactions or for selling or redeeming shares other than an interest (such as compensation or equity ownership) arising from the Covered Officer’s employment by Group or any of its affiliates.

Service as a Director or Trustee. Serve as a director, trustee or officer of any public or private company or a non-profit organization that issues securities eligible for purchase by any of the Price Funds, unless approval is obtained as required by the Group Code.

IV.  Covered Officers’ Specific Obligations and Accountabilities.

A.  Disclosure Requirements and Controls. Each Covered Officer must familiarize himself or herself with the disclosure requirements (Form N-lA registration statement, proxy (Schedule 14A), shareholder reports, Forms N-CEN, N-CSR, etc.) applicable to the Price Funds and the disclosure controls and procedures of the Price Fund and the Price Fund Advisers.

B.  Compliance with Applicable Law. It is the responsibility of each Covered Officer to promote compliance with all laws, rules and regulations applicable to the Price Funds and the Price Fund Advisers. Each Covered Officer should, to the extent appropriate within his or her area of responsibility, consult with other officers and employees of the Price Funds and the Price Fund Advisers and take other appropriate steps with the goal of promoting full, fair, accurate, timely and understandable disclosure in the reports and documents the Price Funds file with, or submit to, the SEC, and in other public

 

3


communications made by the Price Funds.

C.   Fair Disclosure. Each Covered Officer must not knowingly misrepresent, or cause others to misrepresent, facts about a Price Fund to others, whether within or outside the Price organization, including to the Price Fund’s directors and auditors, and to governmental regulators and self-regulatory organizations.

D.  Initial and Annual Affirmations. Each Covered Officer must:

1.  Upon adoption of the Price Funds S-O Code (or thereafter, as applicable, upon becoming a Covered Officer), affirm in writing that he or she has received, read, and understands the Price Funds S-O Code.

2.  Annually affirm that he or she has complied with the requirements of the Price Funds S-O Code.

E.  Reporting of Material Violations of the Price Funds S-O Code. If a Covered Officer becomes aware of any material violation of the Price Funds S-O Code or laws and governmental rules and regulations applicable to the operations of the Price Funds, he or she must promptly report the violation (“Report”) to the Chief Compliance Officer of the Price Funds (“CCO”). Failure to report a material violation will be considered itself a violation of the Price Funds S-O Code. The CCO is identified in the attached Exhibit B.

It is the Price Funds’ policy that no retaliation or other adverse action will be taken against any Covered Officer or other employee of a Price Fund, a Price Fund Adviser or their affiliates based upon any lawful actions of the Covered Officer or employee with respect to a Report made in good faith.

F.  Annual Disclosures. Each Covered Officer must report, at least annually, all affiliations or other relationships as called for in the “Annual Compliance Certification” for T. Rowe Price Group.

V.  Administration of the Price Funds S-O Code. The Ethics Committee is responsible for administering the Price Funds S-O Code and applying its provisions to specific situations in which questions are presented.

A.  Waivers and Interpretations. The Chairperson of the Ethics Committee has the authority to interpret the Price Funds S-O Code in any particular situation and to grant waivers where justified, subject to the approval of the Joint Audit Committee of the Price Funds. All material interpretations concerning Covered Officers will be reported to the Joint Audit Committee of the Price Funds at its next meeting. Waivers, including implicit waivers, to Covered Officers will be publicly disclosed as required in the Instructions to N-CSR. Pursuant to the definition in the Regulations, an implicit waiver means a Price Fund’s failure to take action within a reasonable period of time regarding a material departure from a provision of the Price Funds S-O Code that has been made known to an “executive officer” (as defined in Rule 3b-7 under the Securities Exchange Act of 1934) of a Price Fund. An executive officer of a Price Fund includes its president and any vice-president in charge of a principal business unit, division or function.

B.  Violations/Investigations. The following procedures will be followed in

 

4


investigating and enforcing the Price Funds S-O Code:

1.  The CCO will take or cause to be taken appropriate action to investigate any potential or actual violation reported to him or her.

2.  The CCO, after consultation if deemed appropriate with Outside Counsel to the Price Funds, will make a recommendation to the appropriate Price Funds Board regarding the action to be taken with regard to each material violation. Such action could include any of the following: a letter of censure or suspension, a fine, a suspension of trading privileges or termination of officership or employment. In addition, the violator may be required to surrender any profit realized (or loss avoided) from any activity that is in violation of the Price Funds S-O Code.

3.  Investigations of Whistleblower complaints related to Price Funds will be handled in accordance with the T. Rowe Price Global Whistleblower Policy.

VI.  Amendments to the Price Funds S-O Code. Except as to the contents of Exhibit A and Exhibit B, the Price Funds S-O Code may not be materially amended except in written form, which is specifically approved or ratified by a majority vote of each Price Fund Board, including a majority of the independent directors on each Board.

VII.  Confidentiality. All reports and records prepared or maintained pursuant to the Price Funds S-O Code will be considered confidential and shall be maintained and protected accordingly. Except as otherwise required by law, the Price Funds S-O Code or as necessary in connection with regulations under the Price Funds S-O Code, such matters shall not be disclosed to anyone other than the directors of the appropriate Price Fund Board, Outside Counsel to the Price Funds, members of the Ethics Committee and the CCO and authorized persons on his or her staff.

Adoption Date:    10/22/03

Last Revised:       05/11/2022 (Exhibit B revised)

 

5


Exhibit A

Persons Covered by the Price Funds and

Price ETFs S-O Code of Ethics

David Oestreicher, Executive Vice President and Principal Executive Officer

Alan S. Dupski, Treasurer and Principal Financial Officer

Exhibit B

Dino Capasso, Chief Compliance Officer

 

6